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Professor Garland R. Marshall, Advisor
The epidermal growth factor receptor (EGFR) is a membrane receptor tyrosine
kinase whose over-activation has been implicated to cause many human cancers. Novel
strategies to inhibit the activation of EGF receptors other than the conventional antibodybased and tyrosine kinase inhibitors are virtually non-existent but could provide benefits
both in the laboratory and clinical settings. In an effort to expand the current approaches,
this thesis focused on targeting the homodimerization of the EGF receptors themselves
and the heterodimerization of EGF receptors with the related ErbB2 receptor. Three subprojects were completed in the process. The first project explored the feasibility of
inhibiting the EGF receptor by targeting receptor dimerization with small molecules. Two
lead compounds were initially predicted by virtual screening the NCI compound library,
and were biochemically characterized. The benefit gained from the application of virtual
screening in this project initiated another project to enhance the accessibility of virtual
screening within the non-computational community. The OpenScreening project utilizes
distributed computing resources and provides open-access screening server at:
http://omg.phy.umassd.edu/xvhts. A final project identified the structural mechanism that
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may explain the observed preference of EGFR-ErbB2 heterodimerization over EGFR
homodimerization. Key residues were computationally predicted and biochemically
tested to reveal critical dimerization interface.
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CHAPTER 1. Introduction to the ErbB Receptors
Overview
The epidermal growth factor receptor, EGFR, is the founding member of the ErbB
family of receptor tyrosine kinases that also includes ErbB2, ErbB3 and ErbB41. Among
the members, they share high sequence similarities and adopt a similar spatial domain
arrangement that consists of an extracellular ligand-binding region, a single
transmembrane helix, a juxtamembrane region, a tyrosine kinase domain and a carboxylterminal regulatory region6. Binding of stimulatory ligands to the extracellular domain
induces receptor homo- and heterodimerization that leads to autophosphorylation of the
tyrosine residues in the intracellular regulatory region. Phosphorylated tyrosine residues
serve as docking sites for the recruitment of adaptor proteins which in turn stimulate
downstream pathways leading to enhanced cell proliferation1, 7. Aberrant activation of the
ErbB receptors have long been associated with a wide range of cancers and consequently
established as validated cancer targets8, 9. Current therapeutics fall under two categories:
extracellular-targeting monoclonal antibodies, and small-molecule tyrosine kinase
inhibitors8. Translation from pre-clinical promises to clinical efficacies have been
increasingly challenged by acquired resistance8,

10, 11

. Ongoing studies have pinpointed

escape routes through receptor heterodimerization leading to signal diversification and
amplification as a main evasion mechanism11,
structural

basis

of

the

12

. With crystal structures revealing the

extracellular-mediated

homodimerization

mechanism,

therapeutically targeting the interface with small molecules was one of the main goals put
forth for this thesis. Heterodimeric crystal structures are challenging and perhaps, even
improbable, given the heterogeneity of homo- and heterodimer populations.
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Computational modeling of the interface, prediction of critical residues using the model
and subsequent experimental testing of the predictions represented another main goal.
The rest of this chapter reviews the current state of ErbB receptors and is
organized to reflect aspects with regards to history, biology, and therapeutic implications.
Chapter 2 focuses on the discovery of the first class of small-molecule inhibitors of
EGFR homodimerization. Chapter 3 reports the development of a distributed computing
virtual screen application that initiated from the computational procedures used during
the discovery of dimerization inhibitors. Chapter 4 summarizes EGFR-ErbB2
heterodimer modeling and its subsequent experimental testing of critical interface
residues predicted by the model. Chapter 5 analyzes and elaborates on the additional data
obtained from further development of the initial lead inhibitors

History
The growth factor research field originated here at Washington University in 1952
when Dr. Rita Levi-Montalcini, while working with Professor Viktor Hamburger,
discovered secreted factor in mouse tumour cells that potently promoted neurite
outgrowth in chicken embryos13. This factor was later identified as the nerve growth
factor (NGF) after its purification from snake venom and mouse salivary glands by Dr.
Levi-Montalcini and Professor Stanley Cohen, a postdoc at the time in 195714,

15

.

Professor Cohen then carried on the research as faculty at Vanderbilt to understand why
crude extracts containing NGF from the male mouse salivary gland, but not the purified
nerve growth factor alone, induced early eyelid opening in mouse. Five years later in
1962 (would have been tenure-review time under the current system), Professor Cohen
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described the purification of a 53-amino acid “tooth-lid factor” capable of inducing
“precocious eruption” of teeth and eyelids in newborn mice in 196216. Upon subsequent
studies where he showed that this factor stimulated the growth of epidermis on eyelids17
and the proliferation of epidermal cells18, Professor Cohen renamed this factor as the
epidermal growth factor (EGF)17. These initial discoveries ignited a rapid growth in the
field that led to the identification of the human homolog EGF19-21. Although widelyaccepted that EGF acted by binding to specific receptors22, 23, the actual identification of
its specific receptor, the 170-kDa membrane protein EGF receptor (EGFR), was not until
1978 by Graham Carpenter and Professor Cohen24. Subsequent identification of the
mechanism by which EGFR was phosphorylated upon EGF-stimulation established
EGFR as the first receptor tyrosine kinase (RTK)25-27. In 1985, ErbB2 became the second
member of the ErbB family28, 29, and inadvertently popularized the name “ErbB”. A year
later in 1986, Professor Stanley Cohen and Dr. Rita Levi-Montalcini were awarded a
Nobel Prize to recognize their initial discovery of the growth factors NGF and EGF in
1986. ErbB330 and ErbB431 were eventually discovered in 1989 and 1993, respectively.
Figure 1.1 outlines a timeline of significant events in the field of ErbB receptors.

Figure 1.1. Historic timeline of the ErbB receptors. Adapted from Yarden et al5.
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Another important and often confusing historic aspect of the ErbB field is the
redundancies in nomenclature. Given that the complexity of jargons in a given field is
almost always positively correlated with the length of its history, it is not surprising that
the field of ErbB/EGF/HER/p185, owing to its impact in both pre-clinical and clinical
settings, has accumulated redundancy in describing only four receptors. I gave up tracing
the exact documented origin of the switch from its original intuitive “EGF” to the present
“ErbB” family name. However, based on the fact that ErbB2 was discovered as the gene
“v-erb-b2 erythroblastic leukemia viral oncogene homolog 2”, and that GenBank had just
celebrated its 25th birthday in 2008, I could not help but wonder if this nomenclature
showdown between a gene name and a protein name was an early hint of the budding
impact of bioinformatics. As the references cited in this thesis and in literature span a
broad disciplinary, I am including a jargon look-up table (Table 1.1) for convenience.
Table 1.1. Common names to describe EGFR and ErbB2 receptors
Name
EGFR, ErbB1, Her1
ErbB2, Her2, p185neu, NGL, NEU proto-oncogene, TKR1, c-erbB-2

ID
EGFR
ErbB2

Structure, function and mechanism
Under normal physiological conditions, activation of the ErbB receptors is
controlled by spatial and temporal stimulations with a wide range of ligands. The
evolutionary complexity of the ErbB receptors can be visibly traced to a one-to-one
ligand-to-receptor paradigm in nematode Caenorhabditis elegans where EGFR homolog
LET-23 is stimulated and activated by LIN-3 during vulva development32. In fruitfly
Drosophila melanogaster, the system has evolved into five ligands (Spitz, Gurken,
Keren, Vein, and Argo) and one receptor (DER)33-35. Interestingly, Argo is an antagonist
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that inhibits DER activation, a unique mechanism not found in higher organisms. In
mammalians, the four ErbB receptors are activated by a number of growth factors. ErbB2
currently has no known ligand but instead is thought to be the preferred heterodimer
partner for the members6.
Like all ErbB receptors, EGFR is a receptor tyrosine kinase that is composed of: a
ligand-binding extracellular domain (~620 residues); a single transmembrane alpha helix
(23 residues); a juxamembrane domain (~40 residues); an intracellular kinase domain
(~260 residues); and, a C-terminal tail (~232 residues)5 (Figure 1.2). Binding of
stimulating ligands induces homo- and heterodimerization through a ligand-induced
receptor-mediated interaction of the extracellular domains36. This leads to the activation
of tyrosine kinase domains through the formation of an asymmetric kinase-dimer37
(Figure 1.3). Stimulated kinases phosphorylate specific tyrosine residues in the Cterminal tail of the receptor36 (Figure 1.4). These phosphotyrosines serve as docking sites
for SH2 and PTB domain-containing proteins that promote the activation of multiple
downstream

pathways

and

ultimately

regulate

apoptosis40, and angiogenesis41 (Figure 1.5).
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proliferation38,

differentiation39,

Figure 1.2. Schematic arrangement of EGFR. The
extracellular domain (ECD) has 4 subdomains,
followed by the transmembrane domain (TM), the
juxtamembrane domain (JM), the kinase domain,
and the C-terminal tail (CT). Adapted from
Jorissen et al2.

Figure 1.3. Mechanism of extracellular-driven
dimerization leading to receptor phosphorylation. Upon
EGF binding to the extracellular domain, the receptor
adopts an open conformation exposing the dimerization
arm. Receptor dimerization mediated by the arm induces
the formation of asymmetric kinase dimer and
subsequent kinase activation. Adapted from Bublil, et
al3.

6

Figure 1.4. Signaling phosphotyrosines and the adaptor proteins. Tyrosine residues
identified as autophosphorylation sites are colored yellow. Sites for the Src kinase are
colored in black. Adapted from Olayioye el al4.
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Figure 1.5. ErbB receptor overview. A) Stimulation by a wide range of ligands induces
different combinations of dimerization. ErbB2 and ErbB3 homodimers are rarely found. ErbB2
lacks any known ligands while ErbB3 has non-functional kinase. B) Downstream signaling
cascade propogates signals to control protein expressions. C) Ultimate cell fate decisions.
Adapted from Yarden, et al1.
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Receptor homo- and heterodimerization
ErbB receptor dimerization is a pre-requisite for receptor activation1. ErbB
receptor dimerization is driven by interactions between the extracellular domains of the
two partners42-45. Recent crystal structures of the EGFR extracellular domain homodimer
show that the most extensive part of the dimer interface centers on the intermolecular
interaction between the ß-hairpin dimerization arm (residues 242-259) of one EGF
receptor monomer and a corresponding docking pocket (the “armpit”) on the second
receptor monomer (Figure 1.6). Tyr-246 and Tyr-251 on the dimerization arm appear to
be key residues involved in the stabilization of homodimers as mutation of either of these
residues, even to a conservative Phe ablates dimer formation42, 46. These and the other
residues located on the tip of the dimerization arm of monomer A interacts with residues
that form the “armpit” of monomer B. As with mutation of Tyr-246 or Tyr-251 in the
dimerization arm, mutation of certain residues in the armpit blocks receptor activation.
For example, the R285S/F263A EGF receptor is defective in dimerization and hence its
kinase activity cannot be stimulated by addition of EGF45. These data underscore the
central role played by the dimerization arm in mediating EGFR homodimerization. Given
the high sequence conservation and structural homology of the ErbB receptors, it is likely
that this mode of interaction is conserved within the entire family.

9

Figure 1.6. Crystal structure of the extracellular EGFR homodimer (PDB: 1MOX). A)
dimer in ribbon form. B) Zoomed-in at the dimerization arm-armpit interface.
Y246/Y251 are critical residues on the arm, F263/R285 are critical residues on the
armpit.
EGFR is able to heterodimerize with other members of the ErbB family.
Essentially all combinations of ErbB receptor heterodimers have been shown to exist47, 48
with ErbB2 as the preferred hetero-dimerization partner in all cases48. In fact, ErbB2 is
activated almost exclusively through heterodimerization as it has no known activating
ligand49 and ErbB2 homodimers have not been reported except in highly-overexpressed
states1. ErbB3 is an obligate heterodimerization partner since it has very weak, tyrosine
kinase activity and must utilize the kinase activity of its partner to signal50. All of these
observations lead to the recognition that central to the function of ErbB receptors is their
ability to form dimeric complexes that amplify and diversify the signals generated

Role in cancer and current therapy
The tight association between ErbB receptors and cancer was evident from the
very beginning when ErbB2 was initially discovered because of its oncogenic
potentials29, 51. It is therefore not surprising that they are among the most studied targets
in the paradigm of molecular-targeted cancer therapies8, 52, 53. Perturbation of the EGFR
10

system leads to a variety of tumors in organs including breast54, lung55, ovary56,
pancreas57 and prostate58 (Table 1.2).
Current EGF receptor-directed strategies include monoclonal antibodies that
target the extracellular domain59-61, and small molecule tyrosine kinase inhibitors that
compete with ATP at the nucleotide-binding site of the kinase domain62-64 (Table 1.3).
These drugs are promising, but show highly variable efficacy among patients in clinical
applications38,

65

. Ongoing researches have pointed resistance as a major and an

increasingly substantial challenge. Two most observed resistance are in the forms of
mutations within the ATP-binding site of the kinase domain66, 67 and through homo- and
heterodimerizations leading to signal diversification/amplification12. This is consistent
with

the

reports

homodimerization68,

that
69

tumors

characterized

by

abnormal

levels

of

EGFR

and EGFR-ErbB2 heterodimerization70 often display increased

resistance to current treatments. In this setting, inhibitors that block signaling by multiple
ErbB receptors would likely represent more effective chemotherapeutic agents than drugs
specifically targeting one of the ErbB receptors. Based on the initial development of the
heterodimer-inhibiting pertuzumab71, this strategy must have been conceived by many at
the time when I started this thesis work— additional multi-targeting agents are now being
reported63, 72. Nevertheless, there has not yet been any report of targeting the dimerization
arm with small-molecules. This is likely because that although the concept is fairly
obvious with the availability of the crystal structures, the lack of an appropriate
dimerization assay represents a challenge compared to the already established protocols
for antibody generation and kinase inibition. As described in the next chapter, I embarked
on what was in hindsight a high-risk project to identify small-molecule dimerization
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inhibitors that, with some luck, led to the identification of two lead inhibitors.
Table 1.2. ErbB receptors in cancer (reviewed in 1, 73)
Receptor
Activation
Cancer type
EGFR
Mutation (type III)
Glioma, Breast,
Ovarian

Notes
Deletion of part of
the extracellular
domain yields a
constitutively active
receptor
EGFR
Overexpression
SCCHN, Breast,
Amplification in
Ovarian, Prostate,
40% gliomas,
Kidney, NSCLC,
correlates with
glioma
reduced survival
ErbB2
Overexpression
Breast, Ovarian,
Gene amplification
Stomach, Bladder,
in 15-30% breast
Salivary, Lung
cancers
ErbB3
Expression
Breast, Colon
Co-expression of
gastric, Prostate
ErbB2 with EGFR
or ErbB3 in breast
cancer
Overexpression
Oral squamous cell Overexpression
cancer
reduces survival
ErbB4
Expression
Breast, Prostate,
Co-expression with
Childhood medullo- ErbB2
blastoma
HNSCC, head and neck squamous-cell cancer; NSCLC, non-small-cell lung cancer.
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Table 1.3. ErbB-targeted therapeutics in clinical use (reviewed in 8, 73, 74)
Compound Type
Target Company
Status and comments
Trastuzumab
(Herceptin)
Pertuzumab
(Omnitarg)

Humanized mAb

ErbB2

Humanized mAb

ErbB2

Cetuximab
(Erbitux)

Chimeric mAb

EGFR

ImClone/
Merck KGaA

Matuzumab
(EMD 72000)

Humanized mAb

EGFR

Merck KGaA

Panitumumab
(Vecitibix,
ABX-EGF)
Nimotuzumab
(Thera CIM)

Fully humanized
mAb

EGFR

Abgenix

Humanized mAb

EGFR

YM

Gefitinib
(Iressa,
ZD1839)

Quinazoline TKI

EGFR

AstraZeneca

Erlotinib
(Tarceva,
OSI-774)
Lapatinib
(GW2016)

Quinazoline TKI

EGFR

TKI

EGFR/
ErbB2

Genetech/
Roche/OSI
Pharmaceuticals
GlaxoSmithKline

AEE788

TKI

Novartis

PKI166

TKI

EGFR/
ErbB2/
VEGFR
EGFR

CI-1033

4anilinoquinazoline
irreversible TKI
4Anilinoquinoline3-carbonitrile
irreversible TKI
TKI

EGFR/
ErbB2

Pfizer

EGFR/
ErbB2

Wyeth-Ayerst

EKB-569

Genetech/
Roche
Genetech

Novartis

Approved for the treatment of
ErbB2-overexpressing breast cancer
Phase III trials to treat ovarian
cancer, breast cancer, prostate cancer
and NSCLC; based on its ability to
block ErbB2 dimerization, trials are
ongoing in cancer that express low
ErbB2 levels
Approved for the treatment of CRC;
ongoing trials in combination with
various drugs for treatment of
pancreatic cancer, HNSCC and
NSCLC
Phase II trials for NSCLC,
gynaecological cancer, pancreatic
cancer and oesophageal cancer
Approved for CRC, RCC and
NSCLC
Approved to treat HNSCC, NPC,
glioma; reported reduced toxicity and
immunogenicity
Approved for the treatment of
NSCLC; ongoing trials in HNSCC,
gastrointestinal cancer and breast
cancer
Approved for NSCLC; ongoing trials
in many cancer types
Phase III trial on breast cancer
patients who are refractory to
trastuzumab and chemotherapy
Phase I trials underway—first
multifunction EGFR/ErbB2/VEGFR
inhibitor
Development of PKI166 was
interrupted due to high incidence of
liver toxicity, 17% of patients
showed Grade 3 elevated liver
transaminases
Phase II trials underway in breast and
NSCLC
Phase II trials underway in NSCLC

EXEL
EGFR/
EXELIXIS
Phase I trials underway
7647/EXEL
ErbB2/
0999
VEGFR
CRC, colorectal cancer; HNSCC, head and neck squamous-cell cancer; NPC, nasopharyngeal carcinoma;
NSCLC, non-small-cell lung cancer; RCC, renal-cell cancer; VEGFR vascular endothelial growth factor
receptor
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CHAPTER 2. Targeting EGFR Dimerization with Small-Molecule Inhibitors
Abstract
EGFR dimerization is a prerequisite for activation, and the basis to explore the
feasibility of inhibiting EGFR activation by blocking dimer formation with small
molecules. Initially predicted by virtual screening, subsequent experiments showed that
two compounds dose-dependently inhibited EGFR kinase activation. Both compounds
were shown to block EGF-stimulated dimer formation in live cells using a real-time
luciferase fragment complementation imaging assay. One compound was further shown
to inhibit the growth of HeLa cells. These first-generation lead compounds represent the
first small-molecule inhibitors of EGF receptors that are not directed against the active
sites of the kinase
Introduction
We rationalized that the critical role of extracellular dimerization could be
exploited to inhibit receptor activation, and set out to test the feasibility of targeting the
dimerization process with small molecules. In this chapter, we report the identification of
two small-molecule lead compounds capable of inhibiting the EGFR activation by
blocking dimer formation. These inhibitors were initially identified by applying a
consensus virtual high-throughput screening (vHTS) protocol to screen the National
Cancer Institute Diversity (NCI-Diversity) library75 for compounds with binding potential
to the same pocket that Tyr-246 and Tyr-251 recognize. Subsequent biochemical assays
confirmed that these two compounds selectively impaired EGFR dimerization,
representing the first members of a new class of small-molecule inhibitors of EGFR
activation
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Results
The virtual high-throughput screening protocol (vHTS).
The vHTS employed in these experiments used AutoDock 4.076,

77

to dock

approximately 2000 compounds present in the NCI Diversity database within a 25 Å3
docking box centered on the Tyr-246/Tyr-251 recognition pocket of the dimerization arm
of the EGF receptor. A total of 8 scoring functions were used to independently rank all
predicted docking poses, and the consensus of these functions were chosen as the final
ranking.
The enrichment of a vHTS protocol is typically measured by its ability to recover
true positives as early as possible in a ranked compound library. Protocol evaluation thus
depends on the availability of existing reference active compounds. Because there were
no existing inhibitors that targeted the Tyr-246/Tyr-251 site, it was not possible to
evaluate the enrichment power of our vHTS protocol for the EGF receptor system a
priori. As a result, robustness, measured as the average enrichment across different
protein targets, became a critical criterion for evaluating the performance. Our protocol
was applied to four different protein targets: plasmepsin II (PMII), human cyclindependent kinase 2 (Cdk2), estrogen receptor (ER), and yeast heat shock protein (Hsp90).
Structurally diverse compounds (positives) bound to these protein targets were extracted
from co-crystal structures in the Protein Data Bank, and were mixed with 1926 decoy
compounds (negatives) to construct a testing library. The ability of the vHTS protocol to
recover positives was evaluated using enrichment curve analysis78.
The protocol recovered at least one true positive within the top 1% of the ranked
library for PMII, Cdk2, and ER, and within the top 10% of the library for Hsp90 (Table
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2.1, Figure 2.1). On average, this protocol is expected to recover at least one true ligand
within the top 3.5%, and nearly 2/3 of all ligands within the top 15% of the representative
libraries screened.
Table 2.1: Efficacy and robustness of the vHTS protocol.
Targets

Coverage1%1

Coverage15%

Coverage30%

Coverage50%

Best 2

Cdk2

3%

49%

67%

79%

0.05%

PMII

60%

100%

100%

100%

0.65%

ER

69%

81%

94%

100%

0.05%

HSP90

0%

20%

60%

100%

13.21%

Avg

33%

63%

80%

100%

3.5%

1

Coveragefraction = Number of known actives recovered within the given fraction of the database /
Total number of actives present in the database x 100%
2
Best = ranking of the best predicted active / database size x 100

Figure 2.1. Evaluation of the vHTS
protocol against four testing cases shown
in an enrichment curve analysis. In each
case, multiple known ligands were mixed
in with ~2000 random compounds to
form the screening library. The black
diagonal line represents the random
distribution of active molecules.
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Inhibition of EGFR activation as the primary screen.
We applied the vHTS protocol to the EGF receptor and obtained samples of the
80 top-ranked compounds (top 4%) along with 40 randomly chosen compounds from
NCI for testing. Of the 80 compounds, 4 were not soluble in water or DMSO, and,
therefore, not pursued further. The remaining 76 compounds were tested for their ability
to inhibit EGF-stimulated receptor autophosphorylation in cells at a concentration of 100
µM.
Of the 76 compounds tested, 20 produced a significant (>60%) decrease in
activation as measured by the level of phosphorylation at Tyr-1173, a major
autophosphorylation site on EGF receptors. By contrast, none of the 40 compounds
randomly chosen from the same library inhibited receptor phosphorylation when assayed
under the same conditions. This highlights the enrichment and the utility of our vHTS
protocol in the present system.
Figure 2.2 presents the results for the characterization of what turned out to be the
two lead inhibitors. In both cases, the inhibition was dose-dependent. NSC56452
exhibited an IC50 value of 400 nM while NSC11241 had an IC50 of 12 µM. Despite
having the lowest IC50 value, NSC56452 was not able to achieve full inhibition at
saturating doses.
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Figure 2.2. Inhibition of EGF
receptor autophosphorylation by
NSC11241 and NSC56452. Cells
were pre-incubated with 1% DMSO
for the control, NSC11241 or
NSC56452. Inhibition of EGF
receptor autophosphorylation of the
controls (lane 1 and 2) and
increasing doses of a) NSC11241
and b) NSC56452. Estimated IC50
value quantified from blots for c)
NSC11241 and d) NSC56452.

Specific inhibition of the EGF receptor activation by lead compounds.
To assess the specificity of the 20 candidates, they were tested for their ability to
inhibit two related receptor tyrosine kinases, the insulin receptor and the PDGF receptor.
For the insulin receptor, insulin-stimulated tyrosine phosphorylation of IRS-1 in
differentiated 3T3-L1 cells was assessed79. For the PDGF receptor, PDGF-stimulated
receptor autophosphorylation in NIH3T3 cells was measured80. Neither 3T3-L1 cells nor
NIH3T3 cells express the EGF receptor obviating potential problems associated with
receptor crosstalk.
Of the 20 compounds that inhibited EGF receptor autophosphorylation, 2
inhibited insulin-stimulated IRS-1 phosphorylation and 4 others inhibited PDGF receptor
autophosphorylation (Figure 2.3). An additional 3 compounds markedly enhanced PDGF
receptor autophosphorylation and were not pursued further.
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Figure
2.3.
Specificity
of
inhibitors. Cells expressing either
the insulin receptor or the PDGF
receptor were pre-incubated with
1% DMSO (controls) or 100 µM of
each of the 20 lead compounds. a)
Insulin receptor kinase activity was
assessed
by
measuring
the
phosphorylation of IRS-1 in
response to 3 nM insulin for 1
minute. Representative data of three
experiments. b) PDGF receptor
kinase activity was assessed by
measuring autophosphorylation of
the PDGF receptor in response to 2
nM PDGF for 3 minutes.
Representative data based on two
experiments.
Inhibition of EGF receptor dimerization by lead compounds.
Since the lead inhibitors were initially chosen based on their potential to interfere
with EGF receptor dimerization, we next determined whether the remaining 11
candidates inhibited EGF receptor autophosphorylation by directly blocking receptor
dimerization, as measured by chemical cross-linking. Cells were preincubated with the
inhibitors for 15 min at a final concentration of 100 µM. EGF at 25 nM was then added
followed by 3 mM BS3, a membrane impermeable chemical cross-linker. Figure 2.4
shows the effect of a subset of these inhibitors on the cross-linking of EGF receptor
dimers.
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Figure 2.4. Inhibition of EGF
receptor dimerization determined by
chemical cross-linking assay. Cells
were pre-incubated with 1% DMSO
(lane 1 and 2) or 100 µM of lead
inhibitors (lane 3-6) prior to
stimulation with 25 nM EGF (lane 26) for 5 minutes. All cells were then
treated with 3 mM of the crosslinking reagent BS3. NSC11241 (lane
3) and NSC56452 (lane 5)
significantly inhibit dimer formation.
Lane 4 and 6 show compounds that
did not inhibit dimer formation.
The two lead compounds, NSC11241 and NSC56452, significantly reduced the
formation of high molecular weight dimers while NSC309895 and NSC303769
represented two examples of compounds that failed to block dimer formation. None of
the other compounds had any effect on the cross-linking of EGF receptor dimers.
Because the cross-linker was used at a concentration 30-fold higher than that of the
inhibitors (3 mM vs. 100 µM), it is unlikely that the observed inhibition was due to
quenching of the cross-linking reaction by reaction with the compounds. Consistent with
this conclusion, increasing the concentration of cross-linker BS3 to 5 mM yielded the
same results. It is possible, however, that false negatives could be obtained if reaction of
the compound with cross-linker prevented that compound from binding to the EGF
receptor.
The two hits from the cross-linking assay, NSC11241 and NSC56452 (Figure
2.5), were selected for further testing of the hypothesis that they inhibited dimer
formation. A real-time live cell imaging assay based on luciferase fragment
complementation was utilized to characterize the effect of these compounds on EGF
receptor dimerization81. In this assay, an EGF receptor lacking the entire intracellular
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domain (referred to as ΔC-EGFR) was fused to either an N-terminal (NLuc) or Cterminal (CLuc) fragment of firefly luciferase. Ligand-induced dimerization of the ΔCEGFR brings the luciferase fragments into close proximity resulting in enzyme
complementation and reconstitution of luciferase activity. The rate and extent of receptor
dimerization can, therefore, be measured by following photon flux in the presence of
luciferin. The absence of the intracellular domain of the EGF receptor from these
constructs ensures that compounds affecting luciferase activity without binding to the
cytoplasmic portion of the receptor that contains the tyrosine kinase domain.
As expected, EGF stimulated a rapid increase in light production in DMSOtreated control cells consistent with ligand-induced dimer formation. Cetuximab, an
FDA-approved antibody-based drug that binds to the extracellular domain of the EGF
receptor59,

82

, dramatically decreased EGF-induced luciferase activity, serving as a

positive control for inhibition of dimer formation. At a concentration of 25 µM,
NSC11241 and NSC56452 each induced a significant decrease in luciferase
complementation compared to controls (Figure 2.5).
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Figure 2.5. Inhibition of EGF receptor dimerization assayed by luciferase fragment
complementation. Cells stably expressing ΔC-EGFR-NLuc and ΔC-EGFR-CLuc
were pre-treated with DMSO, the indicated concentrations of compounds or 1 µg/ml
Cetuximab for 20 min in the presence of 0.6 mg/ml D-luciferin prior to the addition of
3 nM EGF. Data represent the change in photon flux between quadruplicates of EGFtreated and untreated control cells. a), NSC11241; b), NSC56452,
To exclude the possibility that the compounds simply inhibited complementation
of the luciferase fragments themselves, they were tested in a similar luciferase fragment
system83 where complementation was induced by the addition of rapamycin to cells
expressing FRB-NLuc and its binding partner CLuc-FKBP. Neither compound induced a
decrease in luciferase complementation at the tested dose (25 µM) in this control system.
This indicates that the observed decrease in complementation in our EGF receptor
complementation assay was not due to any direct effect on the NLuc and CLuc fragments
themselves
NSC56452 and NSC11241 do not inhibit by interfering with the binding of EGF
ligands.
It was still possible that NSC56452 or NSC11241 might inhibit EGF receptor
activation by interfering with the binding of EGF to the extracellular domain of the
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receptor. To address this possibility, the effect of these compounds on the binding of 125IEGF to EGF receptor-expressing CHO cells was measured. NSC56452 had little effect
on EGF binding suggesting that its effect on phosphorylation and dimerization was not
due to blocking the binding of EGF to its receptor (Figure 2.6). NSC11241 had a modest
effect on EGF binding, but the magnitude (~30%) was much smaller than the ~90%
inhibition of receptor autophosphorylation. Thus, an effect on EGF binding is unlikely to
be the predominant mechanism through which NSC11241 exerts its inhibitory effect on
EGF receptor phosphorylation, and certainly not an explanation of NSC56452 inhibition.
Figure 2.6. Effects of NSC56452
and NSC11241 on 125I-EGF binding
and
EGF
receptor
125
autophosphorylation.
I-EGF
binding
and
EGF
receptor
autophosphorylation were assessed
as described in Materials and
Methods. NSC56452 was tested at
100 µM while NSC11241 was used
at 25 µM due to its limited
solubility at 4o C, the temperature at
which the binding assay was
performed.
Growth inhibition of HeLa cells by NSC56452.
To assess the effect of the lead compounds on cancer-cell growth, NSC56452 was
tested for its ability to inhibit the proliferation of HeLa cells that express endogenous
EGF receptors. NSC11241 was not tested here as its color interfered with the MTS cellproliferation assay due to overlap in absorption spectra. For comparison, cells were also
treated with erlotinib, an EGF receptor kinase inhibitor. By itself, NSC56452 induced
significant inhibition of cell growth at 50 µM, but had little to no effect at a lower dose
12.5 µM. Remarkably, the growth inhibition at 12.5 µM NSC56452 was much enhanced
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in combination with a sub-effective dose of erlotinib (Figure 2.7). This apparent
synergistic observation was consistent with the hypothesis that NSC56452 inhibited EGF
receptor activity through a mechanism different from classical kinase inhibitors.
Figure 2.7. Inhibition of HeLa cell
growth. Cells were grown in the
absence or presence of erlotinib,
NSC56452, or a combination of the
two inhibitors at the indicated doses.
Cell growth was measured by the
cellTiter 96 Aqueous One Solution
Cell Proliferation Assay after 48 hr
incubation with the inhibitors. All
experiments were performed in
triplicates. All cultures contained 1%
DMSO.

Discussion
Systematic screening of compound libraries remains the main strategy to discover
novel inhibitors, but lack of appropriate high-throughput bioassays often renders the
approach not feasible in practice. In this work, we were able to bypass this challenge by
utilizing virtual high-throughput screening in combination with low-throughput
biochemical assays to identify lead compounds capable of inhibiting the dimerization and
activation of EGF receptor in intact cells.
In identifying these inhibitors, we adopted a structure-based approach and took
advantage of the recent structural and mutational data that highlight the critical role of the
“dimerization arm” in mediating EGF receptor dimerization42, 44-46, 84. Mutations to Tyr246/Tyr-251 on the arm42, 46 are sufficient to abolish dimerization, suggesting a stringent
structural requirement for these residues to interact with a pair of adjacent hydrophobic
pockets on the other monomer in a precise orientation. We hypothesized that this
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sensitivity to minor perturbations could be exploited to discover compounds capable of
interfering with EGF receptor dimerization.
By testing only 4% of the NCI-diversity library, NSC11241 and NSC56452 were
identified as compounds that selectively inhibited EGF-stimulated tyrosine kinase
activity while having no effect against the related PDGF and insulin receptor tyrosine
kinases. Several lines of evidence suggest that NSC11241 and NSC56452 work by
inhibiting EGF receptor dimerization. In chemical cross-linking assays, both compounds
significantly reduced the formation of EGF-induced high molecular weight oligomers.
This dimer-inhibition mechanism was further confirmed by the luciferase fragment
complementation assay81 where modulation of receptor dimerization by the lead
compounds was quantitatively monitored in real time and in live cells. Interestingly,
AG1478, an EGF receptor kinase inhibitor, has been shown to increase dimer-formation
as measured by both assays81, 85. This difference further supports the conclusion that our
inhibitors inhibit by a mechanism that is distinct from that used by tyrosine kinase
inhibitors. Consistent with this mechanistic difference, NSC56452 and another EGF
receptor-specific tyrosine kinase inhibitor, erlotinib, exhibited synergy with respect to
their ability to inhibit cancer cell growth. In the recent release of the NCI Cancer
Screening Data against 60 cancer cell lines (http://dtp.nci.nih.gov/compare-webpublic_compare/login.do, accessed April, 2009), NSC56452 was reported to inhibit the
growth of 3 cancer cell lines with statistically significant GI50, TGI, and LC50 values:
SK-MEL-586 and UO-3187 cells both overexpress EGF receptors while COLO205 cells
overexpress ErbB288, a related ErbB family of receptors. The apparent correlation
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between sensitivity to NSC56452 and a common molecular target among the cell lines is
consistent with our hypothesized mechanism of action.
This class of dimerization inhibitors provides a new set of chemical tools for
modulating the activation of the EGF receptor in laboratory settings. For example, one
can utilize these compounds to modulate the activation of mutant receptors resistant to
kinase inhibitors, or to gain insights into the formation of EGF receptor dimers and highorder oligomers. In addition to having utility as chemical research tools, these two lead
compounds serve as possible leads for further development as anticancer agents to
complement existing therapeutics.
Materials and Methods
Virtual Screening. Autodock 4.076,
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was used to screen the NCI-diversity database

(1990 compounds). The database was initially downloaded from the Autodock website
and processed by in-house scripts to fix incorrectly formatted structures, and to exclude
structures that contained metals: iron, zinc, mercury and copper (final size = 1926
compounds). A docking box of dimension 25 Å3 was centered at the Tyr-246/Tyr-Y251
recognition site on monomer A of the extracellular dimer crystal structure (PDB:
1MOX). The Larmackian genetic algorithm with Solis and Wets local search was used to
generate 100 docking poses per compound. All poses were subsequently scored using:
HP, HM, HS (implemented in X-score 1.2.189), D-score, PMF, G-score, Chem-score
(implemented in Sybyl 7.3 CSCORE module), and Dfire90. A consensus score for each
pose was calculated by summing the rankings given by each of the 8 scoring functions.
Three compounds that ranked high using the consensus scores were excluded because
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they displayed high rankings against other protein targets suggesting limited specificity
for the dimerization site.
EGF receptor autophosphorylation. CHO cells stably expressing wild type EGF
receptor were grown to 80% confluency in 35 mm plates in Hams’ F-12 containing 10%
FBS, penicillin/streptomycin, and 100 µg/ml hygromycin. Prior to use, the cells were
incubated for 3 hours in F-12 medium containing 0.1% FBS. For the experiments,
cultures were incubated with the test compounds at a final concentration of 100 µM in
1% DMSO for 30 min at 25˚ C in F-12 containing 1 mg/ml bovine serum albumin and
25mM Hepes, pH 7.2. Control cultures were incubated for the same length of time with
1% DMSO. EGF (Biomedical Technologies, Inc) was then added at a final concentration
of 3 nM and the cultures incubated at 25˚ C for an additional 1 min. Subsequently, the
monolayers were washed twice with ice-cold phosphate-buffered saline and scraped into
RIPA buffer (10 mM Tris, pH 7.2, 150 mM NaCl, 0.1% sodium dodecyl sulfate, 1%
Triton X-100, 17 mM deoxycholate, and 2.7 mM EDTA) containing 1 mM sodium
orthovanadate, 20 mM p-nitrophenylphosphate, and protease inhibitors. Equal amounts of
protein (BCA assay, Pierce) were separated by electrophoresis on a 9% SDS
polyacrylamide gel, and transferred to PVDF or nitrocellulose (Millipore). Western
blotting was performed using anti-pY1173 (Cell Signaling), or anti-EGF receptor
antibodies (Cell Signaling and Santa Cruz). Time-course and dose-response experiments
were done using the same procedure except that the dose or preincubation time with
inhibitors was varied. A similar protocol was used for assessing insulin-stimulated
phosphorylation of IRS-1 or PDGF-stimulated receptor autophosphorylation except that
differentiated 3T3-L1 cells or NIH3T3 cells were used, respectively. In all cases,
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phosphorylation was quantified using ImageJ and normalized to that observed in control
samples.
Chemical cross-linking of the EGF receptor. CHO cells stably expressing EGF receptor
were preincubated with the test compounds for 15 min at a final concentration of 100
µM. EGF (25 nM) was then added for 3 min followed by the addition of BS3 (Pierce) at a
final concentration of 3 mM for 30 min. The reaction mixture was buffered at pH 8. The
cross-linking reactions were quenched by the addition of glycine to a final concentration
of 1 M (pH 7.5). Cells were lysed as above, and equal amounts of protein were loaded
onto a 4%-7.5% gradient SDS-polyacrylamide gel. After electrophoresis and transfer to
PVDF, EGF receptor dimerization was measured by Western blotting using anti-EGF
receptor antibodies.
Luciferase fragment complementation imaging. CHO-K1 Tet-On cells stably expressing
ΔC-EGFR-NLuc and ΔC-EGFR-CLuc81 were plated 48 hrs prior to imaging in DMEM
containing 1 µg/ml doxycycline. On the day of imaging, cells were serum-starved for 4
hrs followed by treatment with vehicle, the indicated concentration of each compound, or
1 µg/ml cetuximab for 20 min in the presence of 0.6 mg/ml D-luciferin. 3 nM EGF was
then added and the photon flux immediately measured using an IVIS imaging system.
Data represent the change in photon flux between EGF-treated cells and control cells. For
the control experiments using the FRB-NLuc and CLuc-FKBP system83, 91, CHO-K1 TetOn cells were plated 48 hrs prior to use and transiently transfected with the cDNA
encoding FRB-NLuc and CLuc-FKBP 24 later. On the day of assay, cells were pretreated with vehicle or 80 nM rapamycin for 4 hrs. Media was removed and replaced with
DMEM lacking phenol red containing 0.6 mg/ml D-luciferin and DMSO, 25 µM
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compound NSC11241, or 25 µM compound NSC56452. Photon flux was measured as
above.
125125

I-EGF binding.
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I-EGF binding was carried out by incubating the cells with 50 pM

I-EGF for 24 hr at 4o C, following a previously described protocol92.

Cell Growth Assay. HeLa cells were grown in Dulbecco’s Modified Eagles’ Medium
with 10% FBS. Cells were plated in triplicate in 96-well plates at 5000 cells per well and
allowed to grow for 24 hours before the addition of DMSO (control), erlotinib (Genetech)
or NSC56452. All cultures contained 1% DMSO in the final media. Cells were then
incubated for 48 hours. The cell growth rate was then measured using the cellTiter 96
Aqueous One Solution Cell Proliferation Assay kit according to the manufacturer’s
instructions (Promega). Readings were taken at 490 nm after 1 hour incubation with the
MTS and PMS solution.
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CHAPTER 3. The OpenScreening Project: An Open-Access Virtual Screening Web
Server Powered by Distributed Computing Resources and the Xgrid
Technology
Abstract
Virtual screening of compound libraries against therapeutic protein targets
represents an integral technique in early-stage pharmaceutical drug-discovery. It remains
under-utilized within the academic community due to barriers of insufficient technical
expertise and computing resources. We aim to address this need by making the technique
easily accessible to a broader audience especially those without computational
backgrounds. Towards this goal, we implemented the OpenScreening Project, an openaccess virtual screening web server powered by a grid-computing infrastructure that
integrates an open-source grid manager (GridStuffer) with Xgrid-technology (Apple Inc).
OpenScreening is currently powered by the world’s largest Xgrid cluster of volunteer
CPUs and represents the first open-access virtual screening web application. Functional
since September of 2008, over 80 projects have been completed using CPUs from close
to

500

client

machines.

OpenScreening

can

be

freely

accessed

at

http://openmacgrid.org/xvHTS.
Introduction
Rapid progression in proteomics93-95 has been and will continue to supply a
wealth of novel therapeutic targets for drug discovery. Because the process of translating
target identification into drug discovery still rests in the hands of pharmaceutical
companies, many academic findings of novel targets, particularly those involving rare
diseases, suffer a time-delay in making therapeutic impact. One reason for the apparent
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bottleneck is that large-scale high-throughput screening (HTS) of existing compound
libraries remains the main strategy for identifying lead compounds in the current drug
discovery paradigm96-98. However, given the typical 1 out of 100,000 hit rate from
random screening98, and the pre-requisite investment in developing target-specific highthroughput assays, wide application of industry-comparable HTS at the academic level
remains impractical to most.
Towards alleviating the dependency on HTS, virtual high-throughput screening
(vHTS) has emerged as an integral component in drug discovery for prioritizing
compounds99,

100

. The application of vHTS can enrich the hit rate by several orders of

magnitude101 and, therefore, offers an attractive alternative when high-throughput assays
or screening facilities are inaccessible102-104.
A pre-requisite requirement for running vHTS is its intrinsic demand of
computing resources, a “bottleneck” that explains why, despite its popularity in industry,
the technique remains under-utilized within the non-computational academic community.
One emerging solution for accumulating computing power is through distributed
computing resources105-107, and its utility has been demonstrated by the remarkable
successes of several recent vHTS applications. These applications were tailored for highprofile projects but were not designed to support community-wide access—utilization of
these computing resources is restricted. To address the “bottleneck” by providing
unrestricted distributed computing resources in vHTS applications, we have developed
OpenScreening, an open-access vHTS web server that operates on idle CPUs harvested
from the community. The aims of the project were to (1) provide a validated user-friendly
vHTS tool that lowers the barrier to entry, and (2) present a proof-of-concept computing
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grid

prototype

easily

transferable

for

embarrassingly

parallel

applications.

OpenScreening can be freely accessed at http://openmacgrid.org/xvHTS
Results
Overall workflow. The grid infrastructure is constructed to connect remote client
machines (volunteers) over internet to a central Mac OSX server. Server-client
communications are established by the Xgrid hardware (Apple Inc) while the trafficking
of the communication is maintained by an open-source software, GridStufferr
(http://cmgm.stanford.edu/~cparnot/xgrid-stanford/html/goodies/GridStuffer-info.html).
Upon submission of a new screening project via the web interface, input files are preprocessed to ensure format consistency and placed in queue for execution on the grid.
OpenScreening

currently

operates

on

the

OpenMacGrid

(www.macresearch.org/openmacgrid), the world’s largest Xgrid cluster. During
execution of a screening project, gstuffer dispatches onto available (idle) client machines
a set of concurrent Autodock 4.076, 77 computations each corresponding to the docking of
a compound in the library to the target protein. The process of submission, data retrieval,
and re-submission is iterated until the entire library has been screened. Upon completion,
the compound ranking and the predicted 3D docked conformations are returned as output
(Figure 3.1).
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Figure 3.1: Overall workflow of
the OpenScreening web server.
Inputs and outputs of the
screening projects are submitted
and retrieved via the web
interface,
respectively.
Preprocessing, post-processing, and
analysis are performed by the
server scripts. Parallel docking
runs are executed on the OMG
grid. Grid trafficking and control
are handled by GridStuffer.
Project submission. In the simplest case, a 4-letter PDB code is sufficient for submitting
a new project. In many cases, however, additional insights about specific binding sites of
the target protein are often available for guiding efficient site-directed virtual screening.
To accommodate this, the submission interface incorporates an embedded Jmol108 applet
to support interactive visualization of the protein and docking pocket definition (Figure
3.2). Screening of the NCI-diversity (size 1,990) and Maybridge-diversity (size 14,400)
compound libraries are currently supported, though uploading of customized databases is
possible upon request. OpenScreening currently uses Autodock 4.0 as the backend
docking software, which has been shown to be effective in many cases107,

109, 110

. The

choice of run-time parameters is instrumental to success, thus represents a major source
of uncertainty among novice users. To facilitate in this aspect, we have empirically
derived a set of parameters that displayed a good balance between enrichment power and
speed (see below). These parameters are designated as the default parameters for
OpenScreening. Users are provided with the option of screening with these default
parameters or customized screening parameters. Each project is assigned a password at
submission, which is required for subsequent project cancellation and/or data retrieval.
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Figure
3.2:
Submission
interface. 3 easy steps to
submit a screening project: 1)
visualization and specification
of the docking region of the
protein target; 2) compound
library selection, currently
support the NCI-diversity and
Maybridge HitFinder libraries.
Screening custom libraries
available upon request; 3)
customization of docking
parameters for advanced users
(default
parameters
are
strongly recommended for
most users).
Result retrieval. Internally, each project is split into dockings of individual compounds
to the target protein, which will be independently executed on client machines. These
processes can only be executed under the Xgrid partition pre-designated by Macintosh
under the lowest privilege to ensure absolute integrity of the client machines. Upon
completion, only the result files are transferred back to the server while input and
intermediate files are properly deleted from the client machines. To the end-users, the
rankings of the top 100 compounds and the visualization of their best-predicted
conformation are presented on the result page (Figure 3.3). The complete results, which
include the rankings of all compounds and the complete sets of docked conformation in
multi-mol2 format, can be downloaded on the same page for further analysis offline.
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Figure 3.3: Result retrieval
interface. The ranking and the
corresponding docking pose of
the compounds are presented in
tabular and graphical forms.

Input preprocessing. Input structure files submitted to the central server through the
web interface are first validated to ensure security integrity and format compatibility.
They are used to generate a set of protein descriptions in Autogrid maps, the required
format that feeds into subsequent docking procedures. In theory, docking maps of the
target protein only need to be generated once on the server, transferred to and shared
among all client machines during client-side execution. However in practice, it is more
efficient to recalculate these maps on-the-fly on client machines rather than through
transmission to alleviate the burdens on internet bandwidth. For example, screening
against a target box of 25x25x25(Å3) with grid spacing of 0.2 Å requires 150 megabytes
of map files (the map for each atom type is typically 12 megabytes), or 50 megabytes in
the zipped format. Repeated transmission of 50 Mb data for every docking process is not
practical due to the accumulated amount of input/output communication involving the
central server— minimizing server-client transmission is critical for grid stability and
growth. We also adhere to the policy of strict cleanup on the client machines and choose
not to store these map files remotely. In our implementation, maps are generated once on
the server at the pre-processing stage (before putting in the queue), and are repeatedly
generated on the clients for every docking calculation during execution. The purpose of
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the one-time server-side map generation, besides testing for correct format, provides a
benchmark time that will be used to gauge the relative speed of the individual client
machines. During a client-side docking calculation, the first step is to generate the maps.
The server-side benchmark time is passed along to the clients— machines requiring 5
times longer than the “benchmark” in constructing maps are deemed inefficient and will
not proceed to execute the much more computationally intensive docking calculations.
The decision to not utilize slow machines on the grid currently is based on the
observation that they typically are the last to finish and end up significantly delaying the
completion of the entire project. Our decisions to not exclude slow machines on the grid
in the first place hinges on the understanding that they are useful for less intensive
tasks—for example some machines are not “slow” at calculating tasks that do not require
high cache memory. We also reasoned that dynamically testing the speed on-the-fly,
rather than keeping a local record about the client machines, is advantageous because the
former better accommodates grid flexibility and does not prematurely excludes clients
that underwent upgrades.
Parameter sensitivity analysis. A sensitivity analysis was carried out to evaluate and
determine the performance of a range of Autodock parameters based on accuracy and
time performance. The PDBbind “core set”111, 112 consisting of 69 non-redundant highresolution protein-ligand complexes was used for re-docking-- each ligand was extracted
from the original complex, their torsion angles randomly scrambled, and re-docked back
to its binding protein using different docking parameter combinations (Table 3.1). The
docking boxes were centered at the ligand in the crystal structures, and several box
dimensions were examined in the analysis. The accuracy was defined by 1) sampling: the
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resemblance between the re-docked poses and the original crystal poses as measured by
the root-mean-square distance (RMSD), and 2) scoring: the relative ranking of these
“correct” ligand poses among all generated poses. The RMSD of 2.0 Angstrom113 is
typically the accepted threshold for defining a successful recovery by the docking
protocol though RMSD values in the range of 2.5Å-3.0Å114, 115 have also been commonly
used. For completeness, RMSD thresholds of 1.0, 1.5, 2.0, 2.5, and 3.0 Å were included
when determining the success rates of recovering the crystal poses over 69 complexes
(Figure 3.4, Table 3.2).
Given the number of parameters (6), systematic scanning of each parameter was
impractical—for example, scanning with an interval of just 3 values per parameter would
have yielded 36 x 69 > 50,000 docking computations over 69 complexes. As an
alternative, we chose to test a set of parameter combinations that we have had success
with in the past against various targets. For comparison, the default values given by the
AutoDockTools116 were also included as a reference (denoted as Set 1). With the
exception of Set 1, the differences in sampling accuracy across parameter sets were subtle
under stringent requirement of RMSD 1.0 and 1.5Å (< 10%, Figure 3.4). These results
not only outline the boundary of parameter-dependent improvement in sampling, but also
reiterate the difficulty in docking—it is hard to recover the exact crystal poses. Thus, for
the remaining of our analysis, we focused on the performance using thresholds in the
range of RMSD 2.0-3.0 Å. Under these less stringent but widely-used threshold values,
the best parameter combination (Set 10) achieved a sampling success rate of close to 80%
using RMSD 3.0 Å, and around 60% using RMSD 2.0 Å. However, Set 10 required an
average of 21500 seconds (~6 h) per complex (docking 1 ligand to 1 target), an execution
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time that we considered to be too long and non-ideal for virtual screening using
distributed computing resources—the requirement that a remote client machine needs to
stay idle for 6 hours will drastically decrease the amount of useable nodes on the grid. In
contrast, Set 6 required an average of 1 hour while still displaying good success rates
using thresholds of 2.0-3.0 Å. In addition, Set 2, 3, and 7 also showed good balances
between time and performance attractive for virtual screening applications. These
parameter sets were further analyzed subsequently. All detailed results are summarized in
Figure 3.4 and Table 3.2.
In these initial tests, we kept the dimensions of the docking boxes constant (25 x
25 x 25 Å3, 126 grid points in all 3 dimension with grid spacing of 0.2 Å). We next
evaluated the sensitivity of these parameters to the box dimensions and grid spacing
(Figure 3.5, Table 3.3, Table 3.4). It was not surprising that all parameter sets were
sensitive to the overall box dimensions since smaller docking boxes translated into
improved sampling by eliminating search spaces while larger docking boxes had the
opposite effects. The apparent insensitivity to the grid spacing (Grid 1 vs. Grid 3 Figure
3.5) was unexpected since smaller grid spacing was expected to provide a higher
resolution representation of the protein target and hence better sampling performance.
However, considering that Autodock uses the united-atom representation for the protein
targets76, we reasoned that the difference of 0.1 Å in resolution is not enough to have
significant impacts in sampling.
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Table 3.1. Parameter Sets.
Set # pop_size num_evals
1*
150
2.5 x 105
2
100
2.5 x 105
3
100
2.5 x 105
4
100
5.0 x 105
5
100
1.0 x 106
6
100
5.0 x 105
7
100
1 x 106
8
100
1 x 106
9
100
5 x 106
10
100
5 x 106
11
100
5 x 106
12
30
5 x 106
* AutoDockTools default

elitism_rate
0.01
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.05
0.01
0.05
0.01

mutation_rate
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02

crossover_rate
0.8
0.8
0.8
0.8
0.8
0.8
0.8
0.1
0.8
0.8
0.8
0.8

run
10
50
100
50
50
100
100
100
30
100
100
100

Table 3.2. Performance of using different parameter sets on 69 protein-ligand complexes.
Set #
Avg. Time RMSD
RMSD
RMSD
RMSD
RMSD
(Seconds) < 1.0Å
< 1.5Å
< 2.0Å
< 2.5Å
< 3.0Å
1
120.4
27.5
30.4
37.7
52.2
55.1
2
537.8
26.1
44.9
55.1
65.2
69.6
3
1109.0
31.9
43.5
58.0
62.3
72.5
4
1118.1
26.1
37.7
52.2
62.3
65.2
5
2122.8
26.1
40.6
52.2
60.9
65.2
6
2170.7
30.4
40.6
59.4
68.1
71.0
7
4558.6
31.9
43.5
55.1
63.8
72.5
8
4560.2
31.9
44.9
55.1
63.8
68.1
9
6426.8
26.1
36.2
49.3
58.0
60.9
10
21505.8
30.4
43.5
60.9
68.1
75.4
11
21957.5
30.4
43.5
60.9
66.7
72.5
12
23254.8
27.5
42.0
58.0
66.7
68.1
Table 3.3. Grid Definitions.
Grid Definition # Grid Spacing (Å)
1
0.2
2
0.3
3
0.3
4
0.3

Grid Points
126 x 126 x 126
126 x 126 x 126
84 x 84 x 84
66 x 66 x 66
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Box Dimensions (Å3)
25 x 25 x 25
37.5 x 37.5 x 37.5
24.9 x 24.9 x 24.9
19.5 x 19.5 x 19.5

Table 3.4. Percentage of complexes correctly re-docked
under different grid definitions.
Parameter Set
Grid 1
Grid 2
RMSD < 1.0 Å
2
26.1
20.3
3
31.9
24.6
6
30.4
29.0
7
31.9
26.1
RMSD < 1.5 Å
2
44.9
31.9
3
43.5
33.3
6
40.6
34.8
7
43.5
40.6
RMSD < 2.0 Å
2
55.1
43.5
3
58.0
43.5
6
59.4
46.4
7
55.1
50.7
RMSD < 2.5 Å
2
65.2
50.7
3
62.3
55.1
6
68.1
58.0
7
63.8
56.5
RMSD < 3.0 Å
2
69.6
53.6
3
72.5
62.3
6
71.0
60.9
7
72.5
66.7
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using several parameter sets
Grid 3

Grid4

31.9
30.4
31.9
33.3

29.0
34.8
33.3
31.9

36.2
42.0
44.9
42.0

42.0
49.3
46.4
43.5

50.7
59.4
59.5
53.6

60.9
60.9
69.6
59.4

59.4
66.7
66.7
63.8

71.0
73.9
75.4
68.1

62.3
72.5
75.4
69.6

79.7
79.7
79.7
76.8

Figure 3.4. Re-docking of 69 protein-ligand
complexes to compare sampling accuracy among 12
parameter sets. Sampling accuracy was defined by
using a range of RMSD values (1.0-3.0 Å) between
the docked ligand poses and the crystal poses. The
percentage of complexes with docked poses within
the RMSD thresholds of crystal poses are plotted
against the average execution time for the docking
process. Set 6 displayed a good balance between
accuracy and execution time.

Figure 3.5. Sensitivity of Parameter Set 6 to grid
definition. Grid definitions specify the grid spacing
and the dimensions of the docking box (see table 3.3).
For each definition, the percentage of 69 complexes
with at least 1 docking pose within the specified
RMSD values of crystal structures are shown in the
bar graph.
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The next level of analysis was focused on the sensitivity to the scoring aspects of
Autodock— how well the “correct” docking poses rank relative to the decoy
counterparts. All parameter combinations showed good and comparable discriminatory
power to favorably rank the “correct” docking poses. On average, these “correct” docking
poses were ranked within the top 5-10% of all generated poses on average over 69
complexes (Table 3.5). Given that all but 1 parameters (the “number-of-energyevaluations” parameter) under consideration deal with the stochastic sampling process
(genetic algorithm), these results suggest that the “number-of-energy-evaluations”
parameter, despite having little sensitivity in improving scoring, still can impact the
docking outcome because of the coupling of sampling and scoring in the genetic
algorithm.
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Table 3.5. Ranking powers of each parameter sets under different grid definitions.
Average Ranking of the Best-Ranked Correct Docking Pose
Calculated as: (best ranking/number of generated docking poses) x 100%
Param Set
< 1.0 Å*
< 1.5 Å
< 2.0 Å
< 2.5 Å
< 3.0 Å
Grid 1
1
8.0
8.0
8.0
11.2
12.6
2
6.6
8.0
8.1
11.3
12.7
3
6.3
10.3
9.8
9.5
12.5
4
4.5
6.4
9.0
10.9
11.9
5
4.6
7.1
8.0
9.7
11.1
6
7.2
7.7
7.9
9.1
9.0
7
8.9
9.3
9.8
11.5
13.4
8
6.6
9.8
8.4
10.4
11.3
9
7.0
7.6
8.4
11.4
11.3
10
7.2
8.8
11.1
12.4
16.3
11
7.5
10.4
10.7
11.1
14.2
12
5.1
8.6
8.3
10.8
10.1
Grid 2
2
2.3
4.3
5.3
5.1
5.1
3
2.1
4.4
4.4
6.9
7.9
6
33
4.1
3.9
5.2
6.1
7
4.7
6.8
7.5
7.4
12.5
Grid 3
2
6.9
7.0
8.9
10.2
12.1
3
6.9
7.4
9.1
9.2
12.7
6
5.6
5.2
6.3
9.1
9.2
7
5.6
7.4
8.8
9.8
11
Grid 4
2
5.6
6.1
9.0
11.7
15.3
3
6.4
8.9
9.1
11.5
13.4
6
7.8
9.9
12.7
14.1
13.7
7
6.9
6.7
8.9
10.6
13.3
* Correct poses are defined by RMSD values between the docked poses and the crystal
pose; a range of RMSD thresholds are examined here.
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Figure 3.6. Virtual screening of a
synthetic compound library (~2000
molecules) against 4 protein targets.
Parameters were taken from
parameter Set 6. The area-undercurve
(AUC)
measures
the
enrichment power in each case.

Further testing of the parameters in the context of vHTS. To evaluate these
parameters in a vHTS context, we performed cross-docking experiments using the
OpenScreening webserver. A synthetic compound library of 2000 compounds that
included known actives was screened against 4 protein targets similar to the protocol
described in Chapter 2. The 4 protein targets were plasmepsin II (PMII), cyclin
dependent kinase 2 (CDK2), estrogen receptor (ER), heat-shock protein 90 (HSP90).
Each protein target had a rich collection of protein-ligand co-crystal complexes in the
PDB. These ligands were mixed with 1926 NCI-diversity compounds to form the
synthetic compound library. The PDB accession codes used for cross-docking of known
ligands to the four protein targets were: plasmepsin II (PMII), 1LEE, 1LF2, 1LF3, 1M43,
1ME6, 1W6H, 1W6I, 1XE5, 2BJU, 2IGX; cyclin dependent kinase 2 (CDK2), 1AQ1,
1CKP, 1DI8, 1DM2, 1E1V, 1E1X, 1E9H, 1FVT, 1G5S, 1GIH, 1GZ8, 1H00, 1H01,
1H07, 1H08, 1H0V, 1H0W, 1H1P, 1H1Q, 1H1R, 1H1S, 1JSV, 1JVP, 1KE5, 1KE6,
1KE7, 1KE8, 1KE9, 1OGU, 1OI9, 1OIQ, 1OIR, 1OIT, 1OIU, 1OIY, 1P2A, 1P5E, 1PF8,
1PKD, 1PXI, 1PXK, 1PXL, 1PXM, 1PXN, 1PXO, 1PXP, 1PYE, 1R78, 1URW, 1V1K,
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1VYW, 1VYZ, 1W0X, 1WCC, 1Y8Y, 1Y91, 2A4L, 2B52, 2B53, 2B54, 2B55, 2BPM,
2BTR, 2BTS, 2C68, 2C6K, 2C6L, 2C6M, 2CLX, 2FVD, 2UZB, 2UZD, 2UZL; estrogen
receptor (ER), 1A52, 1ERR, 1L2I, 1SJ0, 1UOM, 1X7E, 1X7R, 1XP1, 1XP6, 1XP9,
1XPC, 1XQC, 1YIM, 1YIN, 1ZKY, 2AYR, 2B1V, 2FAI, 3ERD, 3ERT; heat-shock
protein 90 (HSP90), 1A4H, 1BGQ, 1BRE, 1YC1, 1YC3, 1YC4, 1ZW9, 2BRC, 2CGF.
The protein structures with the highest resolution structures in each case were: 1LEE
(HSP90), 2B54 (CDK2), 1XPC (ER), and 2BRC (HSP90). All bound small molecules
were manually separated from the complex and prepared using OpenBabel v2.0.2117.
Using the respective highest resolution protein structures, we virtual screened this
testing library against all 4 targets with parameter Set 6. The efficiency to rank active
compounds higher than the decoy compounds (referred to as the enrichment power) was
evaluated by measuring the fraction of active compounds that are present within the top
fraction of the entire ranked library. The corresponding enrichment curve (Figure 3.6)
plotted the progression of enrichment over a continuous fraction range and was quantified
by calculating the area-under-curve (AUC). As shown in Figure 3.6, these parameters
displayed a significant trend for favorably ranking the active compounds in all 4 cases—
at least one active compound was identified within the top 1-5% of the library. In the best
case (ER), half of the actives were recovered within the top 10% of the entire library.
The speed of OpenScreening was assessed by running the same virtual screening
experiment against the ER target using a local cluster of 50 nodes. OpenScreening
exhibited an overall 10-fold increase in the number of compounds screened at its peak
(Fig. 3.7, Table 3.6). Screening ~2000 compounds was completed in less than 24 hours,
whereas the same processes took nearly 5 days on the local cluster.
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Figure 3.7: Wall-clock time
performance of OpenScreening
comparing to that of a local
computer cluster (50 nodes).
The OpenScreening protocol
consistently displays 10-fold
increase in wall-clock time over
the local cluster at its peak. The
plateau reflects the bottleneck
effects of slow client machines
on the grid.

Table 3.6. Bench mark of CPU and wall-clock time.
Screening Targeta Total CPU Total Docking Average CPU hours per Total Wall-clock
hours
Runsb
Docking Run
hours
CDK2
1278.3
2607
0.49
19.1
ER
1350.5
2573
0.52
22.8
PMII
1442.5
2508
0.58
21.7
HSP90
1479.8
2504
0.59
22.9
ER_local cluster 985.2
2415
0.41
116.3
a
CDK2, cyclin-dependent kinase 2; ER, estrogen receptor; PMII, plasmepsin II; HSP90,
heat shock protein 90; ER_local cluster, the same screening project against the estrogen
receptor performed on a local computer cluster (the average number of running nodes
during the execution was 25).
b
Total docking runs included resubmissions.
Usability. Over 80 projects spanning several research groups, most having no
computational backgrounds, have been performed by OpenScreening since being
functional in September of 2008. On average, screening of the NCI-diversity library takes
overnight, and screening of the Maybridge library takes 5 days. We have been rigorously
testing the stability of OpenScreening in anticipation of a rapid increase in user base upon
publication.
Prototype for Xgrid-based applications. VHTS, like all “embarrassingly parallel”
applications, has a repetitive nature that demands robust traffic-coordination algorithms
that exceed the capability of the primitive Xgrid scheduling system alone. In addition,
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intrinsic dependence on remote client-side executions renders these grid applications
susceptible to high-error rate that often requires extensive human interventions118. In our
design, three independent layers of controls by Xgrid, GridStuffer, and the vHTS wrapper
script were implemented to address these challenges. Through the Xgrid server-client
socket, GridStuffer transfers the Autodock executable, the protein and compound
structure files, along with the wrapper script to the Xgrid-designated partition on the
client machines. Upon completion, only the result files are transferred back to the server
while the rest of the files are properly deleted. The decision to decouple these layers
allowed us to independently address, at different abstraction levels, problems that are
inherent to distributed computing and specific to vHTS. Xgrid handles errors associated
with server-client transmission and notifies GridStuffer of the communication status of
individual clients. Based on these client statuses, GridStuffer schedules submission,
result- retrieval, and resubmission of failed tasks which are flagged by the return value of
the vHTS wrapper scripts. Given that Xgrid and GridStuffer were both designed to be
application-agnostic, this protocol can be readily adapted for other embarrassingly
parallel applications by changing at the application-specific wrapper script level.
Discussions
The capacity of OpenScreening already exceeds the computing resources of many
private corporate counterparts119, 120, demonstrating the advantage of being supported by
the community. However, it clearly cannot compare to the well-established grid-based
projects such as FightAIDS@Home107 (~450,000 nodes) or the Screensaver Project106
(~3.5 million), nor was it ever our intent. Our goal is to provide a broad research
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audience with a tool that addresses the need of unrestricted accessibility to vHTS and
encourages the integration of computational tools in the non-computing community.
The integration of Xgrid and GridStuffer presents an affordable and easy-toimplement utility to build grids among research labs, departments, institutions, and units
of essentially any size. Because Xgrid is an inherent feature of the OS X platform, grid
expansion does not require explicit software installations on each machine. Volunteers
can join the OpenScreening grid by simply entering the address of the OpenMacGrid grid
server (step-by-step instructions on the website). However, this also restricts the client
machines to be only Mac machines running OS10.4 or later. The development of
middleware to include PC machines is anticipated to further expand the grid size, though
efficient recruitment of PC machines would most likely come in the form of pre-existing
clusters rather than individual volunteers. The requirement to explicitly install client-side
communication portal compatible with the PC middleware demands a level of
complication that is better suited for experienced system administrators. Some of the
viable open-source middleware frameworks include ACE and TAO from the Center of
Distributed Object Computing (http://www.cs.wustl.edu/~schmidt/doc-center.html), and
Opal

from

National

Biomedical

Computation

Resources

(http://www.cs.wustl.edu/~schmidt/doc-center.html). Alternatively, collaborations with
the drugdiscovery@home project (http://drugdiscoveryathome.com/) that uses the
Berkely Open Infrastructure for Networked Computing (BOINC) may be possible if the
concept of unrestricted open-access can be preserved.
Parameter Set 6 was set as the default parameters for the OpenScreening
webserver for its robust sampling and ranking powers as well as its fast execution time.

48

Most of the other parameters tested in this chapter also did not result in significant
deviations in performance. In particular, Set 2 and Set 3 displayed ¼ and ½ average
execution time comparing to that of Set 6, respectively. These parameters therefore are
expected as good candidates for screening larger libraries without significantly
compensating for accuracy.
Shortcomings in the current implementation will be improved in future updates.
One example is the rate-limiting effect of slow client machines on the overall
performance. Stagnant performance towards the end stage of a screen project (Figure 3.7,
number of docked compounds plateaus towards the end) can dramatically prolong the
overall wall-clock time. Despite a 10-fold increase at its peak over the local cluster
(Figure 3.7), the increase in the overall wall-clock time to complete a screening project
was only 5-fold (Table 3.6, ER vs ER_local). One way to address this issue is to increase
the map generation “benchmark time” thresholds from its current 5x to 10x in order to
eliminate the use of slow machines. A more elegant solution under testing, however, is to
trigger redundant scheduling of multiple docking instances of the same ligand onto
several client machines concurrently towards the end of a screening project—the first
successful results from these duplications will abort the other instances, thus completing
the project.
In addition to using Autodock, we are also exploring the possibility of including
additional docking softwares and scoring functions to the OpenScreening webserver.
Docking softwares using systematic search algorithm and/or incorporating receptor
flexibility may improve the current sampling efficiencies of 60-80%. The benefit of using
multiple scoring functions is apparent by comparing the enrichment power of using the
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Autodock scoring function alone (Figure 3.6) and that of using the consensus scoring
scheme described in Chapter 2 (Figure 2.1). We expect that by providing the options of a
wide range of docking and scoring softwares, OpenScreening will improve its accuracy
as well as extend its utility to a larger user-base. As we aim to implement additional
components and functions onto OpenScreening, our long-term goal is to stimulate the
integration of computational tools in generating reasonable hypothesis to help with
designing and performing subsequent experiments.
Acknowledgements. The OpenScreening project would not have been possible without
help from Dr. Charles Parnot and the OpenMacGrid community. Charles is the inventor
of the GridStuffer software
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Appendix 3.1: Instructions to set up Xgrid and GridStuffer.
Equipment.
•

Mac OS X Server 10.4 or later.

•

GridStuffer freely available for download at
http://cmgm.stanford.edu/~cparnot/xgrid-stanford/html/goodies/GridStufferinfo.html.

Equipment setup.
•

Configure server according to manual.

•

Install GridStuffer and set it to run as a launchd application:

•

> launchctl load /Library/LaunchDaemons/org.openmacgrid.xgridstatus.plist

•

> launchctl load /Library/LaunchDaemons/org.openmacgrid.gstuffer.plist
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Applendix 3.2: User manual of the OpenScreening webserver.
Submission to OpenScreening (Figure 3.2)
1 From the OpenScreening homepage, navigate to the “submit task” tab or go directly to
the website (http://omg.phy.umassd.edu/xvHTS/submit/). Accept the applet certificate for
Jmol when prompted, this allows the visualization using the Jmol applet.
2 Specify an email address for notification of the job status.
3 Supply a valid target structure in PDB format either by specifying its PDB code or
uploading a file. Structure must be displayed to continue.
CRITICAL STEP Validate the format of the file before submitting. It is highly advised
that the file only contains coordinates for common amino acids. Ions and other molecules
should be deleted from the file. Sometimes water molecules can cause problems as well.
Only PDB format is supported at this time.
4 Specify docking site by changing the location and size of the docking box. Small
molecules will only be docked onto areas enclosed by the docking box.
5 Select small molecule libraries to screen. Press Shift while clicking to select multiple
libraries (depending on individual keyboard setup).
6 Customize screening parameters only if you are an advanced user. Default parameters
are highly recommended.
7 Submit and wait for a confirmation number. Successful submissions will be assigned a
confirmation number and displayed in the queue.
Cancellation of a project in the queue.
8 From the OpenScreening homepage, navigate to the “queue” tab or go directly to the
link (http://omg.phy.umassd.edu/cgi-bin/queue.cgi). Locate the project to be cancelled in

52

the queue list. Click on the “cancel” link and input the assigned confirmation number
when prompted.
Retrieval of screening results (Figure 3.3).
9 From the OpenScreening homepage, navigate to the “queue” tab or go directly to the
link (http://omg.phy.umassd.edu/cgi-bin/queue.cgi). Locate the project that has been
completed in the queue list. Click on the “view job” link and input the assigned
confirmation number when prompted.
TROUBLESHOOTING
Join the grid (voluntary).
10 Follow the link http://www.macresearch.org/contribute_to_openmacgrid for a step-bystep instruction.
Troubleshooting
Table 3.7. Troubleshooting table.
Step Problem
Solution
3
Structure is not Make sure it has a valid PDB format. Try another browser with
displayed
javascript enabled.
7
Submission
Delete from the structure file: non-standard amino acids, all
failed
HETATM records, ANSIOU records and all alternative
coordinates if they exist.
8
Cannot
locate Contact us: http://omg.phy.umassd.edu/xvHTS/contact/
the cancel link

9

Do not know Contact us: http://omg.phy.umassd.edu/xvHTS/contact/
confirmation
number
Cannot
locate Contact us: http://omg.phy.umassd.edu/xvHTS/contact/
the results
Do not know Contact us: http://omg.phy.umassd.edu/xvHTS/contact/
confirmation
number
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CHAPTER 4. Computational Modeling and Experimental Testing of the ErbB2EGFR Heterodimer Interface
Abstract
Like EGFR homodimers, the formation of ErbB2-EGFR heterodimers is thought
to be mediated by inter-molecular interactions between the extracellular domains. Given
that the ErbB2-EGFR heterodimers have been associated with elevated transforming
potentials, this protein-protein interaction serves as an attractive target to extend the
development of dimer inhibitors. However, the molecular interface is unknown in the
absence of crystal structures. By using crystal structures of the EGFR homodimer and the
ErbB2 monomer as templates, a model of the EGFR-ErbB2 extracellular heterodimer
constructed by homology modeling and further refined using molecular dynamics
simulation. Comparison between the ErbB2-EGFR heterodimer model and EGFR
homodimer revealed subtle difference at the respective dimer interfaces. Based on the
heterodimer model, two negatively-charged residues, both unique to ErbB2, were
computationally predicted and experimentally confirmed to be critical for the stability of
the ErbB2-EGFR interface. The identification of these critical residues and the
heterodimer interface model serve as potential target sites for the development of
heterodimer inhibitors.
Introduction
ErbB2, a close homolog of the EGFR (64% sequence similarity)2 in the ErbB
receptor family, is the preferred heterodimerization partner of all other ErbB family
members48,

121

, but rarely homodimerizes among themselves122-124. Like EGFR, ErbB2

has a structural domain arrangement that consists of an extracellular domain, a
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transmembrane helix, and an intracellular catalytic kinase domain122. In contrast to EGFR
and the rest of the ErbB family members, ErbB2 has no known ligand and constitutively
adopts the open conformation where the homologous extracellular subdomain II, termed
as the “dimerization arm” in EGFR, is readily exposed for interaction with a partner ErbB
receptor123,

124

. As described in Chapter 2, inter-receptor interactions mediated by the

dimerization arm drives the formation of EGFR homodimer44, 45. Mutations to critical
residues on the arm result in complete disruption of homodimers thus underlining the
necessity of preserving this interface42,

46

. This dimer interface centered on the

dimerization arm and its respective docking pocket is thought to be universal for the
EGFR-ErbB2 heterodimer and among all other ErbB dimers.
Given that EGFR-ErbB2 heterodimers exhibit enhanced signaling and are often
associated with aggressive tumors68,

125

, understanding the molecular details of the

heterodimer interface carries important implications for developing cancer therapeutics.
Crystal structure of the extracellular EGFR-ErbB2 heterodimer has not been solved most
likely due to the presence of heterogeneous populations of homo- and hetero-dimers.
Crystal structures of the extracellular EGFR in the homodimeric form and ErbB2 as
monomers have been solved recently – the monomeric state of these ErbB2 structures
reflects the weak propensity of ErbB2 to homodimerize. In an attempt to probe the
EGFR-ErbB2 interface, a heterodimer model was built by homology modeling using the
crystal structures of the extracellular EGFR homodimer and ErbB2 monomer as
templates. The homology model was subsequently refined by an all-atom molecular
dynamics (MD) simulation. Computational mutagenesis based on the refined model
coupled with experimental site-directed mutagenesis led to the identification of two “hot-
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spot” residues located on the ErbB2 dimerization arm that are essential for
heterodimerization. The heterodimer model along with the knowledge of the hot-spot
residues not only offer structural interpretations of different combinations of dimers, but
also serve as roadmaps for the development of heterodimer-disrupting peptidomimetics.
Results
Model refinement
The EGFR-ErbB2 heterodimer homology model was subjected to full-atom
molecular dynamic (MD) simulations in explicit water for the purpose of further relieving
unfavorable interactions. For reference, the EGFR homodimer crystal structure (PDB
1IVO) was also relaxed using the same MD setup in parallel. In both cases, simulations
of these large systems in the short time-frames generated only conformations in the
vicinity of a low-energy structure— experimental crystal structure for homodimer, and an
energetically stable heterodimer homology model.
Stability and similarity of the global dimer conformations during simulations
Molecular dynamic simulations often require time to relieve unfavorable
interactions and equilibrate the starting structures into energetically stable ensembles.
Root-mean-square-distance (RMSD) with respect to simulation time is a standard method
for separating the initial relaxation phase (rapid increase) from a low-energy local
minimum production stage (plateau). Based on the RMSD profiles in Figure 4.1, we
chose the production run to start at time 3500 ps for the heterodimer simulation, and 2000
ps for the homodimer simulation.
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Figure 4.1. Root-mean-squaredeviation of homo- and heterodimer MD simulations.

The high degree to which secondary structures were preserved from the starting
structures during refinement (Figure 4.2) suggested the presence of a low-energy local
minimum configuration similar to the starting structures. The number of residues found
in well-defined secondary structures was comparable in both homo- and hetero- dimer
simulations highlighting an overall similarity in global domain arrangement. These
results are consistent with the basis for homology-modeling— the justification to use
ErbB2 and EGFR as homology templates because they shared similar global spatial fold.
MD simulations, interpreted as relaxations rather than dynamics given the scope of
sampling, did not cause significant alterations to the overall global structure during
refinement of the starting heterodimer model into a more energetically favorable
configuration. Preservation of this global structural similarity between homo- and heterodimers can be visualized by a representative snapshot (Figure 4.3).
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Figure 4.2. Number of
residues observed in each
secondary structure as a
function of time. Values were
extracted
every
50
picoseconds for clarity.

Figure 4.3. Global view of the heterodimer
(A) and homodimer (B) extracted from a
representative snapshot from MD. The box
region indicates the arm interface. The
snapshots represent the frames with the
lowest energy calculated by the MM/PBSA
method. T1 and T2 denote to the location of
reverse-Turn 1 and Turn 2.
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Differences at the “arm-armpit” interface
The tip of the arm of both ErbB2 and EGFR consisted of five consecutive
residues that formed two overlapping reverse-turns at the dimer interface (Figure 4.3).
Reverse-turns are among the best-characterized structures for their importance and
therapeutic potential as recognition motifs in protein-protein interactions126. The
molecular conformations of these two reverse-turns, denoted as Turn 1 and Turn 2, were
classified and compared at different interfaces: 1) EGFR-arm/ErbB2-armpit, 2) ErbB2arm/EGFR-armpit, and 3) EGFR-arm/EGFR-armpit. Analyses were carried out using the
ensemble of snapshots in the production stage of the simulations, as well as using the
static crystal structures (Table 4.1). Both the canonical127 and Tran128 reverse-turn
definitions were used for classification— the canonical classification is based on
backbone dihedral angles while the Tran classification measures the relative side-chain
orientations by calculating the Cα-Cβ vectors.
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Table 4.1 Conformation summary of the reverse-turns at different interfaces
EGFR dimer crystal ErbB2 monomer crystal Homodimer simulation
(PDB: 1IVO)
(PDB: 2A91)

Heterodimer
simulation

Canonical Definition
Turn1
EGFR arm
Turn1
ErbB2 arm

IV

n/a

IV(93%), I(7%)

IV(66%), I(34%)

n/a

IV

n/a

IV(99%), I(1%)

Tran Definition
Turn1
EGFR arm

3

n/a

3(81%), 5(10%), 1(9%)

3(79%), 1(10%),
5(11%)

Turn1
ErbB2 arm

n/a

3

n/a

3(98%), 6(2%)

Canonical Definition
Turn2
EGFR arm

I

n/a

IV(100%)

I(93%), IV(7%)

Turn2
ErbB2 arm

n/a

IV

n/a

IV(97%), VIII(3%)

Tran Definition
Turn2
EGFR arm

8

n/a

8(66%), 6(16%), 2(10%),
5(7%), 7(1%)

8(81%), 2(9%),
5(7%), 6(3%)

Turn2
ErbB2 arm

n/a

2

n/a

6(45%), 8(43%),
2(1%), 7(1%)

Turn1 of EGFR arm defined as: 247N 248P 249T 250T
Turn2 of EGFR arm defined as: 248P 249T 250T 251Y
Turn1 of ErbB2 arm defined as: 254N 255T 256D 257T
Turn2 of ErbB2 arm defined as: 255T 256D 257T 258F
Numbers in brackets denote to the percentage of ensembles adopting the corresponding classifications

Because of limited sampling, we restricted our interpretations at the qualitative
level. In the crystal structures, Turn 1 of EGFR and ErbB2 both adopted the poorlydefined Type IV backbone conformation by canonical definition—Type IV is defined as
“all conformations that do not fit the other Types”. The Type IV configuration of Turn 1
was predominantly preserved during homo- and hetero- dimer simulations, although a
higher fraction of heterodimer snapshots exhibited variations in adopting dihedral angles
characteristic of the well-defined Type I configuration. This observed shift towards
ordered backbone configurations may be a product of a less favorable initial heterodimer
model and a reflection of the adjustment at this arm-armpit interface. In contrast to the
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predominantly “unclassifiable” backbone configurations, the side-chain orientation of
Turn 1 could be precisely characterized as Tran Cluster 3 in all cases. This suggested that
surface interactions, in both intra- and inter- molecular forms, were well organized and
maintained.
Turn 2 of EGFR adopted the Type I configuration in the homodimer crystal
structure, but shifted entirely to Type IV during the homodimer simulation. On the other
hand, Type I was the predominant configuration for EGFR Turn 2 in the heterodimer
simulation, highlighting the difference likely induced by the differences at homo- and
hetero- dimer interfaces. Turn 2 of ErbB2 adopted the “unclassifiable” Type IV backbone
conformation in crystal structure and stayed “unclassifiable” during heterodimer
relaxation. The side-chain orientation
of EGFR Turn 2 was preserved as
predominantly Tran Cluster 8 in all
but one case. The side-chains of
ErbB2 Turn 2 had two even Tran
clusters
Figure 4.4. Reverse-turn 2 at the tip of the arm
extracted from the representative snapshot of
the heterodimer simulation. Structures ErbB2
(red) and EGFR (green) were superimposed to
outline the difference in both the backbones and
side-chains.

during

the

course

of

heterodimer simulations suggesting
the possibility of relaxed degrees of
freedom at the ErbB2-arm/EGFRarmpit interface.

To summarize, the reverse-turns of the EGFR and ErbB2 arms adopted different
structural configurations at different interfaces. Figure 4.4 shows an example snapshot to
compare Turn 2 of ErbB2 with that of EGFR in the heterodimer simulation. Despite
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global structural similarity, the reverse-turns at the tip of the dimerization arm exhibited
subtle configuration differences. We rationalized that these differences in arm
configuration were likely dictated by the nature of the interaction environment provided
by the armpit counterparts.
To test this rationalization, inter-receptor contact maps centered on the EGFR and
ErbB2 arms were examined in homo- and hetero-dimer simulations (Figure 4.5). In the
heterodimer complex, the EGFR arm was shown to contact a larger set of ErbB2 armpit
residues than the ErbB2-arm/EGFR-armpit counterparts (Figure 4.5A). This is an
indication that despite global symmetry (Figure 4.3), the dimer interface is asymmetric in
nature where the EGFR arm extends into a tighter pocket that result in an increased level
of heterodimer receptor contacts. This is in contrast with the relatively symmetric
interface observed in the homodimer complex (Figure 4.5B). Among the four examined
cases, the ErbB2 arm showed the fewest number of contacts with its partner.
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Figure 4.5. Contact maps of A) heterodimer and B) homodimer
simulations. In each panel, the X-axis shows residue numbers from
the corresponding arm region. The Y-axis shows residue numbers
from the respective dimer partner.
Buried solvent-accessible surface area (SASA) was calculated at the interface to
further characterize the nature of these inter-receptor contacts (Figure 4.6). Consistent
with the contact maps, the EGFR-arm/ErbB2-armpit interface qualitatively had more
buried SASA than that of the ErbB2-arm/EGFR-armpit interface. Most of the interactions
were hydrophobic in nature. Likewise, the homodimer interface was also dominated by
hydrophobic interactions, but had much less buried SASA (Figure 4.6B).
Figure 4.6. Solvent-accessible
surface areas of the arm and
armpit
regions
from
A)
heterodimer simulation and B)
homodimer simulation. EGFR_A
and EGFR_B denotes to chain A
and B in the homodimer.
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Based on the reduction in buried hydrophobic SASA at the ErbB2-arm/EGFRarmpit interface, we visualized a few snapshots at this interface and noted the presence of
two negatively-charged residues, D256/E259, located at the tip of the ErbB2 dimerization
arm. Sequence alignment of the dimerization arm region among all ErbB family members
showed that both D256/E259 residues are unique only to ErbB2 (Figure 4.7). We
therefore wondered if the two charged residues on the ErbB2 arm may compensate the
reduction in intermolecular contacts by participating in favorable salt-bridge and
hydrogen-bonding networks.
The presence of hydrogen-bonding network around the ErbB2 arm (residue 252262) was analyzed. A positively charged residue, R285 in the EGFR armpit was
identified as a hydrogen-bond partner with both D256 and E259 in majority of the
snapshots. This suggested that these interactions are favorable within the scope of our
sampling and consistent with the logic that these interactions can compensate for the loss
in hydrophobic interactions. As shown visually in Figure 4.8, the side-chain carboxyl of
D256 on the ErbB2 arm forms a salt-bridge interaction with the side-chain guanidino
group of R285 in the EGFR armpit, while the side-chain carboxyl of E259 interacts with
the backbone amide of R285 (Figure 4.8A). By comparison, the EGFR arm extends
deeper into the ErbB2 armpit, thus creating additional surface contacts that, without
charged residues, are largely hydrophobic interactions (Figure 4.8B). In the homodimer
complex, the presence of R285, but not the corresponding D256 and E259, restricts the
size of hydrophobic contact surface and weaker hydrogen bonds are formed to replace the
salt-bridge (Figure 4.8C). Interestingly, R285 is present in all ErbB receptors except for
ErbB2 where it is substituted with a leucine, a hydrophobic residue (Figure 4.7). It is
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possible that this may contribute to explain why ErbB2 receptors do not homodimerize.
Figure 4.7. Sequence alignment of all 4 ErbB
family members around the arm and armpit
regions. Arrows indicate substitutions unique to
ErbB2. Using ErbB2 residue numbers, they are
D256/E259 and L292.
Figure 4.8. Representative
snapshot of the arm-armpit
interface between A) ErbB2
arm-EGFR
armpit,
B)
EGFR-arm/ErbB2-armpit;
and C) EGFR arm- EGFR
armpit. A and B are from
the heterodimer simulation
while C comes from the
homodimer simulation.
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Computational mutagenesis
To further elucidate the molecular basis of preference for formation of the ErbB2EGFR heterodimer, we extended the analysis of the dimer models by introducing
mutational perturbations to map out residue contributions critical for dimer stability. This
analysis is based on the concept that protein interfaces are often dominated by the
energetic contributions from only a handful of “hot-spot” residues129,

130

— as already

seen in the mutation studies of Tyr-246/Tyr-251 in the context of EGFR homodimer.
Two computational methods, independent in theory and different in computational costs,
were utilized to calculate a consensus prediction of mutational effects. The MM/PBSA131
method calculates the relative binding free energy by decomposing the overall free
energy into individual components; in contrast, the Rosetta132 protocol predicts the
relative stability of the dimer complex using fast empirical scoring functions. In both
cases, the results were averaged over an ensemble of snapshots extracted randomly from
each simulation. It is important to emphasize that these calculations were based on
limited sampling with the intention of assessing the stability rather than dynamics of the
complexes. As explained below in the control assessments, the interpretations will be
strictly at the qualitative level.
Computational mutagenesis by MM/PBSA
The predictability of the protocol was evaluated by conducting calculations on a
set of experimentally characterized mutants of the EGFR homodimer42, 46: Q194A had
little effect on dimer formation; D279A/H280A significantly but not completely
disrupted dimer formation; the Y251 and Y246 mutants completely abolished dimer
formation. Qualitatively, MM/PBSA predicted the rank order of the mutants in excellent
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agreement with the experimental ranking (R2=0.94) (Figure 4.9A). Although MM/PBSA
has been previously reported to quantitatively reproduce experimental binding energy, we
did not expect the same accuracy due to limited sampling and, therefore, restrict all of our
subsequent interpretation at the qualitative level.
Figure 4.9. Comparison of the
predictive powers between A)
MM/PBSA
and
B)
Rosetta
protocols using mutants with
known
experimental
values.
Experimental values were obtained
from literatures described in text.

Based on the contact map and hydrogen-bonding analysis, 20 mutants (Table 4.2
and 4.3) around the arm-armpit interface were computationally constructed and
calculated to compare with the wildtype homo- and hetero- dimers. All heterodimer
mutants were predicted to have detrimental effect on dimerization (Table 4.4, Figure
4.10) consistent with the initial design rationale that weakening the electrostatic
interactions at the ErbB2-arm/EGFR-armpit interface and the hydrophobic interactions at
the EGFR-arm/ErbB2-armpit interface would disrupt dimer formation. Qualitatively, the
D256R/E259K mutation on the ErbB2 arm (mut4) and the T249D/Q252E mutation on
the EGFR arm (mut7) were predicted to have the largest detrimental effects. This
supports the rationale that the former shifts a previously favorable electrostatic
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interaction with residue R285 of the EGFR armpit to an unfavorable repulsive
interaction, while the latter introduces hydrophilic residues into an environment
dominated by hydrophobic interactions. Likewise, unfavorable mutations at the
corresponding armpit regions (mut10: R285L in EGFR and L292R in ErbB2) were
predicted to significantly weaken dimerization.
In contrast, the equivalent electrostatic or hydrophobic interactions are absent at
the EGFR homodimer interface (Figure 4.8C). Several putative enhancing mutants aimed
at restoring electrostatic or hydrophobic interactions were included to investigate the
possibility of interface optimization (Table 4.3). Despite our design, all mutants were
predicted to be detrimental in nature by MM/PBSA (Table 4.5 and Figure 4.10A).
Qualitatively, mutants 2 and 4 were predicted to have lesser detrimental effect consistent
with the initial design purpose to retain hydrophilic-hydrophobic balance. Mutant 6 and 8
were designed to be enhancing by mimicking the ErbB2 armpit, but were instead
predicted to have a small detrimental effects. The other putative enhancing mutants, 3
and 7, designed to mimic the charged ErbB2, were predicted unfavorable by MM/PBSA.
A detailed look at the energy contributions showed that it was actually the weakening of
the electrostatic interactions that contributed the most to the unfavorable binding energy
in both cases (Table 4.4).
One possible explanation for the inconsistency between MM/PBSA predictions
and our hypothesis could be due to insufficient minimization of the local environment
during mutant calculations. As hinted by our earlier analysis on reverse-turns, dynamics
of these interface residues likely involved a combination of backbone and side-chain
flexibilities. Since our MM/PBSA protocols kept the backbones constant, substitution of

68

a neutral, small wildtype residue with a long, charged residue (T246D) was unlikely to
have enough space to relieve steric clashes and establish hydrogen-bonding networks as
hypothesized. Towards testing this theory and improving accuracy, we repeated the same
sets of mutant calculations using the BACKRUB module132 of Rosetta, which
implemented the backrub motion133 to account for side-chain-mediated backbone
flexibility.
Figure 4.10. Computational
mutagenesis using homo- and
heterodimer simulations. A)
MM/PBSA predictions and B)
Rosetta predictions.
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Table 4.2. Description of heterodimer mutants
Mutation Mutation details
Region
Rationale
ID
mut1
B2:D256A/E259A
ErbB2 arm Alanine-scan
mut2

B2:D256N/E259Q

ErbB2 arm Mutate to noncharged
equivalence
ErbB2 arm Mutate to EGFR
equivalence

mut3

B2:D256T/E259Q

mut4

B2:D256R/E259K

ErbB2 arm Charge reversal

mut5

B2:L292R

ErbB2
armpit

Mutate to EGFR
equivalence

mut6

B2:T291V/L292R/V293A

ErbB2
armpit

Mutate to EGFR
equivalence

mut7

B1:T249D/Q252E

EGFR arm Mutate to ErbB2
equivalence

mut8

B1:R285L

EGFR
armpit

Mutate to ErbB2
equivalence

mut9

B1:V284T/R285L/A286V

EGFR
armpit

Mutate to ErbB2
equivalence

mut10

B2:L292R, B1:R285L

mut11

B2:D256T/E259Q,
B1:T249D/Q252E

EGFR and Mut5 + Mut8
ErbB2
armpit
EGFR and Mut3 + Mut7
ErbB2 arm
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Hypothesis
Weaker ErbB2 arm
–EGFR armpit
interface
Weaker ErbB2 arm
–EGFR armpit
interface
Weaker ErbB2 arm
–EGFR armpit
interface
Much Weaker
ErbB2 arm –EGFR
armpit interface
Weaker EGFR arm
–ErbB2 armpit
interface
Weaker EGFR arm
–ErbB2 armpit
interface
Much weaker
EGFR arm –ErbB2
armpit interface
Weaker ErbB2 arm
–EGFR armpit
interface
Much weaker
ErbB2 arm –EGFR
armpit interface
Weaker at both
interfaces
Weaker at both
interfaces

Table 4.3. Description of homodimer mutants
Mutation Mutation details
Region
ID
mut1
T249A/Q252A
EGFR arm (1
monomer)
mut2
T249N
EGFR arm (1
monomer)
mut3
T249D/Q252E
EGFR arm (1
monomer)
mut4
R285L
EGFR armpit
(1 monomer)
mut5
T249D/Q252E/R285L EGFR arm and
armpit
mut6
V284T/R285L/A286V EGFR armpit
(1 monomer)
mut7
Double T249D/Q252E EGFR arm
(both)
mut8
Double
EGFR armpit
V284T/R285L/A286V (both)
mut9
Double
EGFR arm and
T249D/Q252E/R285L armpit
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Rationale

Hypothesis

Alanine-scan

Weaker interface

Non-charged
mutation
Mutate to ErbB2
equivalence
Mutate to ErbB2
equivalence
Mut3 + Mut4

Weaker or little
effect on interface
Stronger interface

Mutate to ErbB2
equivalence
Mut3 on both
monomers
Mut6 on both
monomers
Mut5 on both
monomers

Stronger interface

Weaker or little
effect on interface
Weaker interface

Stronger interface
Stronger interface
Weaker interface

Table 4.4. MM/PBSA predictions on heterodimer mutants
coul

wt

-184.0
(7.3)
mut1 -64.6
(6.4)
mut2 -70.2
(8.4)
mut3 -70.0
(7.5)
mut4 -60.5
(7.3)
mut5 -170.7
(7.5)
mut6 -142.9
(7.4)
mut7 -80.1
(7.1)
mut8 -51.0
(7.8)
mut9 -21.1
(8.1)
mut10 -71.1
(7.0)
mut11 -3.8
(7.3)

Vdw

-84.8
(1.1)
-86.3
(1.2)
-89.8
(1.1)
-89.0
(1.3)
-91.1
(1.3)
-88.9
(1.3)
-88.1
(1.2)
-88.1
(1.3)
-88.4
(1.2)
-90.0
(1.3)
-89.2
(1.6)
-89.3
(1.5)

Polar

247.9
(7.7)
146.3
(6.5)
155.4
(7.9)
155.0
(8.2)
158.9
(7.6)
257.8
(7.9)
229.7
(8.8)
170.2
(8.9)
129.6
(8.0)
110.9
(8.1)
160.3
(7.2)
99.4
(7.7)

Apolar

-20.1
(0.2)
-19.5
(0.2)
-20.1
(0.2)
-20.0
(0.3)
-21.0
(0.2)
-20.1
(0.2)
-20.0
(0.3)
-20.1
(0.2)
-19.8
(0.2)
-19.7
(0.3)
-19.8
(0.3)
-19.9
(0.3)

coul+pol vdw+apol coul+vdw pol+apol

64.4
(2.1)
82.8
(3.0)
85.8
(2.8)
84.0
(3.4)
98.4
(3.3)
83.4
(3.1)
85.1
(3.9)
90.5
(3.2)
77.7
(2.3)
88.8
(3.6)
86.6
(3.1)
95.1
(3.4)
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-104.9
(1.3)
-105.7
(1.4)
-109.7
(1.2)
-109.2
(1.4)
-111.9
(1.6)
-109.2
(1.5)
-108.2
(1.5)
-108.1
(1.4)
-108.2
(1.3)
-109.9
(1.5)
-108.8
(1.8)
-108.6
(1.7)

-265.9
(7.3)
-151.0
(6.2)
-160.7
(7.8)
-159.0
(7.0)
-151.7
(7.1)
-258.7
(8.5)
-232.1
(7.4)
-167.7
(7.1)
-139.4
(8.3)
-110.1
(8.4)
-160.8
(7.4)
-92.6
(8.2)

227.4
(7.7)
126.5
(6.4)
135.0
(7.8)
134.6
(8.1)
137.9
(7.5)
237.6
(7.7)
208.7
(8.7)
150.5
(9.0)
109.6
(7.9)
92.9
(8.0)
140.5
(6.9)
78.9
(7.4)

Total

-39.7
(1.9)
-22.9
(2.3)
-23.0
(2.6)
-24.2
(2.4)
-14.1
(2.5)
-24.5
(2.3)
-22.5
(2.7)
-17.5
(2.2)
-30.2
(2.0)
-20.9
(2.5)
-23.8
(2.9)
-13.9
(2.3)

Delta

0
16.8
(1.9)
16.7
(2.1)
15.6
(1.7)
25.6
(4.8)
15.2
(1.6)
17.2
(2.3)
22.2
(3.0)
9.5
(0.8)
18.9
(2.4)
15.9
(2.1)
25.8
(4.4)

Table 4.5. MM/PBSA predictions on homodimers
coul

Wt
mut1
mut2
mut3
mut4
mut5
mut6
mut7
mut8
mut9

-119.0
(14.1)
-73.6
(5.4)
-120.8
(9.9)
-104.8
(6.8)
-85.0
(7.3)
-91.5
(6.0)
-76.7
(7.5)
-120.2
(7.5)
-39.9
(5.5)
3.0
(8.0)

Vdw

-83.2
(1.6)
-84.0
(1.7)
-85.2
(2.3)
-86.6
(2.6)
-83.0
(1.5)
-87.3
(2.6)
-84.5
(1.4)
-88.3
(2.7)
-85.9
(1.7)
-87.5
(2.3)

Polar

180.8
(13.3)
143.5
(7.4)
183.9
(13.1)
183.0
(8.7)
147.9
(8.7)
169.8
(6.7)
144.5
(10.8)
200.1
(9.3)
112.6
(7.3)
83.7
(8.6)

Apolar

-18.5
(0.8)
-17.9
(1.0)
-18.5
(0.5)
-18.4
(0.5)
-18.2
(0.4)
-18.1
(0.4)
-18.1
(0.8)
-18.3
(0.5)
-18.1
(0.5)
-18.0
(0.5)

coul+pol vdw+apol coul+vdw pol+apol

59.8
(3.0)
68.2
(4.3)
65.93
(3.0)
74.2
(3.8)
63.8
(3.0)
77.1
(2.7)
65.3
(4.1)
85.4
(4.2)
71.3
(3.0)
90.1
(3.8)
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-102.0
(2.4)
-102.4
(2.7)
-104.2
(2.5)
-105.0
(3.2)
-101.0
(1.6)
-105.6
(3.2)
-102.8
(2.6)
-107.0
(3.1)
-103.8
(2.1)
-105.5
(2.7)

-202.0
(15.7)
-158.8
(6.4)
-203.6
(13.3)
-191.9
(8.5)
-169.0
(8.6)
-178.5
(7.3)
-163.8
(8.7)
-205.6
(9.4)
-126.6
(6.6)
-83.1
(9.0)

160.9
(13.8)
125.2
(9.7)
165.8
(12.8)
164.9
(8.0)
131.1
(7.6)
151.0
(7.0)
124.6
(12.0)
183.9
(8.1)
95.2
(7.0)
65.8
(8.4)

Total

-41.3
(3.3)
-34.0
(3.7)
-37.9
(2.9)
-30.4
(3.7)
-36.9
(2.5)
-27.8
(3.9)
-36.1
(3.3)
-20.8
(3.9)
-32.2
(2.2)
-14.7
(3.6)

Delta

0
7.3
(1.0)
3.5
(0.4)
10.9
(1.6)
4.4
(0.5)
13.5
(2.2)
5.3
(0.6)
20.5
(4.2)
9.2
(1.0)
26.6
(7.0)

Computational mutagenesis by Rosetta
The same set of control mutants was utilized to implement, optimize, and evaluate
the Rosetta protocol. Comparable to the MM/PBSA protocol, excellent agreement with
qualitative experimental rankings were observed by the Rosetta protocol (R2=0.88)
(Figure 4.10B).
In contrast to the MM/PBSA predictions, Rosetta predicted, among the
homodimer mutants, that the T246D/Q252E mutant (mut3) to be an equal, or slightly
more favorable mutant than the wildtype (Figure 4.10B, right). The other mutants
hypothesized to be either neutral (mut2, 4) or enhancing (mut6, 7) were all predicted to
be closer to wildtype than the corresponding MM/PBSA predictions. Mutant 8 was
designed to have enhancing mutations on both arms (mutant 6 has the same enhancing
mutations on only 1 arm), but was predicted to be unfavorable contrary to our
expectations.
In the heterodimer mutants (Figure 4.10B, left), predictions on almost all mutants
followed a similar trend as the MM/PBSA predictions, which we interpret as
convergence of the two protocols. The glaring exceptions were the armpit mutants L292R
of ErbB2 (mut5) and R285L of EGFR (mut8) which Rosetta assessed at a much reduced
penalty compared to MM/PBSA. This was likely an example of over-compensating
unfavorable interactions by over-estimating flexibility.
Comparison between MM/PBSA and Rosetta
Both MM/PBSA and Rosetta were adequate at predicting loss-of-function
mutations (Figure 4.10). The two protocols displayed a high correlation in predicting
mutants carrying two or less substitutions (Figure 4.11A). However, it is likely that

74

because of the differences in flexibility-sampling algorithms, the correlation decreased as
the number of simultaneous substitutions increased (Figure 4.11B). Furthermore,
backbone movement intrinsic to the BACKRUB module of Rosetta may have been more
forgiving at predicting potentially enhancing mutations, but possible overestimation of
flexibility also may reduce its discriminatory power rendering the protocol potentially
susceptible to false positives.
The magnitudes of the free energy differences by MM/PBSA protocol are in
general too high to be interpreted as realistic quantitative predictions (> 10 kcal). This is
likely due to its inherent incorporation of several independent softwares at the
implementation level. For example, the spatial positions of the mutant residues were
sampled and minimized using PLOP forcefield, whereas the corresponding MM energies
were calculated using OPLSAA as implemented in Gromacs—the same protein structure
will likely yield to different energy magnitude dependent on the forcefield parameters. So
while these structures can be considered as locally “favorable” in both forcefields, the
degree may be different which translates. For future improvement, we speculate that
minimizing the PLOP-generated mutant structures in OPLSAA forcefield before
calculating the MM energies should lower the absolutely magnitude of energy difference.
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Figure 4.11. Correlation and
convergence pattern between the
MM/PBSA and Rosetta protocols.
A) Correlation graphs of mutants
with 2 or less substitutions and all
mutations. B) Summary of all
mutations
categorized
by
substitution numbers.

Experimental examination of mutant predictions
Four ErbB2 arm mutants (mut1-4, respectively: D256A/E259A, D256N/E259Q,
D256T/E259Q, D256R/E259K), predicted to have varying degrees of detrimental effect
on heterodimer formation, were experimentally tested for their effect on heterodimer
activation and dimerization efficiency in cells. Based on the correlation analysis of the
MM/PBSA and Rosetta protocol, we restricted the choice of mutant to two substitutions
and chose to focus on the D256/E259 mutants that were unanimously predicted to disrupt
dimer formation by both protocols.
Reduced activation of ErbB2 mutant-EGFR heterodimers by Western Blot
To determine the effect of mutation of the ErbB2 arm on activation of the ErbB2EGFR heterodimer, each ErbB2 mutant was transiently transfected into CHO cells stably
expressing the kinase-dead K721A-EGFR134. This choice of EGFR mutant ensures that
the kinase-dead EGFR can only be activated through heterodimer formation. Activation
of the K721A-EGFR in the heterodimer was measured in each of the mutants and was
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compared with wild-type ErbB2 by Western blotting for phosphorylation of the K721AEGFR (Figure 4.12). We confirmed that phosphorylation could not be detected by
homodimerization of ErbB2 or kinase-dead EGFR alone (Figure 4.12A, last two lanes).
Any detectable EGF-stimulated phosphorylation must therefore be due to the formation
of K721A-EGFR/ErbB2 heterodimers. Compared to cells expressing wildtype ErbB2
receptors, phosphorylation was hindered in all 4 mutants as predicted (Figure 4.12B).
Among the mutants, D256R/E259K almost completely abolished phosphorylation,
supporting both the prediction and hypothesis that electrostatic interactions between the
wildtype ErbB2 arm and the EGFR armpit at this interface was critical for heterodimer
formation.

Figure 4.12. Phosphorylation of heterodimers
formed by wildtype and mutant ErbB2
receptors.
A)
Phosphorylation,
EGFR
expression, and ErbB2 expression in the
presence and absence of EGF stimulations. B)
Quantification of phosphorylation per receptor
level.

Reduced dimerization of the EGFR by luciferase fragment complementation imaging
upon expression of ErbB2
To directly monitor the mutant effect on heterodimer levels, a luciferase fragment
complementation imaging assay81 was utilized to measure the degree at which the
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mutants can compete for wildtype EGFR in live cells. The extracellular domain of the
EGFR that lacks the entire intracellular domain was fused just beyond the transmembrane
domain to an N-terminal luciferase fragment (ΔC-EGFR-NLuc) and the complementing
C-terminal luciferase fragment (ΔC-EGFR-CLuc). The ΔC-EGFR-NLuc and ΔC-EGFRCLuc constructs were stably co-expressed in CHO-K1 Tet-On cells. On the day of
imaging, cells were pre-treated with the firefly luciferase substrate, D-Luciferin for 20
min to allow equilibration of the intracellular and extracellular pools of the substrate. A
baseline photon flux was then measured, followed by addition of ligand and measurement
of photon flux every 30 sec for 30 min.

Figure 4.13. Heterodimer competition measured by real-time quantification of
EGFR homodimer level in the presence of wildtype and mutant ErbB2
receptors using split-luciferase complementation imaging assay. A) Photon
emitted by the complementation of NLuc-EGFR and CLuc-EGFR upon
transfection of wildtype and mutant ErbB2 under non-stimulating (top) and
stimulating (bottom) conditions. B) Summary of A. C) Quantification of the Ymax from the stimulating conditions. D) ErbB2 receptor level of the transfected
cells immediately after imaging.
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Upon transient transfection of wildtype or mutant ErbB2 receptors into these
cells,

formation

of

either

ΔC-EGFR-NLuc/ErbB2

or

ΔC-EGFR-CLuc/ErbB2

heterodimers is expected to decrease the population of the signal-emitting ΔC-EGFRNLuc/ΔC-EGFR-CLuc homodimers. The competing power of the wildtype and mutant
ErbB2 receptors were assessed by monitoring their ability to “quench” the photon flux
from formation of the ΔC-EGFR-NLuc/ΔC-EGFR-CLuc homodimers. As a reference,
the competing power of wildtype EGFR without the luciferase fragment was also
assessed. As expected, wildtype ErbB2 was able to quench the photon flux better than the
wildtype EGFR, (Figure 4.13) since heterodimer formation is favored over homodimer
formation. All ErbB2 mutants, except for one, displayed weaker photon flux quenching
than wildtype ErbB2. Consistent with the phosphorylation data, the D256R/E259K
mutant had the weakest competing power among all ErbB2 receptors. The expression
levels of the wildtype and mutant ErbB2 receptors were measured immediately after
imaging using Western blot analysis with an ErbB2 antibody to ensure signal differences
were not due to an unequal number of receptors in each case. In the absence of EGF, the
basal photon flux was reduced in all cases compared to cells transiently transfected with
empty vector. This data is consistent with the notion of pre-formed dimers135-138 and that
these pre-formed dimers are disrupted in a similar competing fashion upon transient
transfection with the wildtype or mutant ErbB2 receptors. Interestingly, the magnitude of
the decrease in the basal photon flux appears to be identical in all cases, suggesting that
the preformed dimers utilize an interface independent of the ErbB2 arm.
Discussion
The series of systematic analysis of the computationally refined EGFR-ErbB2
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heterodimer model progressively led to a set of experimentally testable hypothesis
centered on the dimerization arm interface. The initial focus on the two ErbB2 charged
residues D256 and E259 originated from analyzing the nature of molecular contacts at
different dimer interfaces. The contrast at the dimer interfaces led to subsequent sequence
alignment where it was observed that D256/E259 residues are unique to ErbB2. Upon
mapping these residues onto the tip of the arm, the backbones and side-chains of two
overlapping reverse-turns were classified to reveal that Turn 1 of EGFR and ErbB2
adopted similar configurations independent of surrounding residues. By contrast, Turn 2
displayed different range of backbone and side-chain conformations which highlighted a
preference of environment-specific flexibility and orientations. This was explained by the
contact map analysis (Figure 4.5) where Turn 2 residues were associated with a higher
number of inter-receptor contacts, thus requiring specific spatial adjustment to
complement corresponding armpit configurations. For example, the ErbB2-arm/EGFRarmpit interface had reduced number of inter-receptor contacts but appeared to be
energetically favorable due to the presence of a salt-bridge hydrogen-bond network
between D256/E259 of ErbB2 and R285 of EGFR. This observation led us to examine
the sequence alignment of the R285 region and subsequently identified the unique
substitution of a leucine residue in place of the arginine in ErbB2.
The EGFR-ErbB2 heterodimer model presented here provides, among many
biological interests, a structural basis to explain the absence of an ErbB2 homodimer.
Using the EGFR homodimer interface as a reference (Figure 4.8C), the EGFR-ErbB2
heterodimer has two energetically more favorable interfaces—electrostatic interactions
between D256/E259/R285 at the ErbB2 arm-EGFR armpit interface (Figure 4.8A), and
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extensive inter-receptor hydrophobic contacts at the EGFR armpit-ErbB2 arm interface
(Figure 4.8B). The hypothetical ErbB2 homodimer on the other hand, is likely to pay a
hefty energetic penalty for extending the D256/E259-containing arm of one monomer
into the highly hydrophobic armpit of the other monomer where the complementary
charged arginine is replaced by leucine. This conclusion that homodimerization of the
ErbB2 extracellular domains is energetically unfavorable is in agreement with previous
reports that the rare occurrences of full-length ErbB2 homodimers requires additional
interactions between the transmembrane139 and intracellular37, 140, 141 domains. Although
Garret and colleagues had arrived at the same conclusion based on the ErbB2 monomer
structure124, they speculated based on crude estimation of surface electrostatic potential
that electrostatic repulsion between ErbB2 arm and armpit was the reason for unfavorable
ErbB2 homodimerization. Our current work supports part of this notion but further
extends the analysis to pinpoint the unfavorable interactions at the residue level using a
relaxed all-atom model.
Among the tested mutants, D256R/E259K displayed the biggest detrimental effect
at disrupting heterodimer. This observation is consistent with the analysis that the ErbB2arm/EGFR-armpit interface is normally stabilized by the presence of strong electrostatic
interactions involving residues D256/E259 and the R286 residues. However, replacing
the electrostatic attractions with the unforgiving repulsion consequently elevates the
energetic barriers of heterodimer formation. D256A/E259A and D256N/E259Q displayed
smaller effects in the luciferase competition assay (figure 4.13) most likely because these
neutral substitutions did not introduce enough energy penalties to significantly disrupt the
interface. Because the substitutions were of smaller (D256A/E259A) or comparable
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(D256N/D259Q) size with the wildtype counterparts, they likely did not introduce
additional steric penalties in the predominantly hydrophobic EGFR armpit so that the loss
of electrostatic interactions alone in these cases was not enough to raise the energetic
barrier to the same degree as introducing repulsion penalties. Similar logics should be
applicable to the D256T/E259Q mutants. However, in stark contrast to D256A/E259A
and D256N/E259Q, we actually observed an apparent lower level of heterodimer
“quenching” comparable to that of the D256R/E259K mutant (Figure 4.13). We
rationalized that this may be a result of the ability to homodimerize among the
D256T/E259Q mutant ErbB2s since this pair of substitutions mimics the EGFR
dimerization arm (Figure 4.7) — this is equivalent to the EGFR-arm/ErbB2-armpit
interface. Indeed, in the phosphorylation assay we observed an elevated ligandindependent basal phosphorylation for the D256T/E259Q mutants (Figure 4.12)
consistent with the concept of spontaneous ErbB2 mutant dimerization.
The experimental confirmation of D256/E259 as “hot-spot” residues serves as
good support for the heterodimer model. An immediate application of this work is to
design homo- or heterodimer specific therapeutics. Virtually all existing small-molecule
inhibitors of ErbB receptors arose from the current paradigm of targeting the kinase
catalytic site of individual ErbB receptors142. Recent awareness and understanding of the
heterodimer-mediated drug-resistance12,

143-145

has accelerated the development of the

dual kinase inhibitor lapatinib63 and has warranted efforts towards multi-targeting146.
Understanding the structural differences at the homo- and heterodimer interfaces provides
new target sites and roadmaps for designing small-molecule inhibitors to target ErbB
family dimers of all combinations. For example, reverse-turn 2 at the tip of the arm can
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serve as promising structural templates for designing reverse-turn peptidomimetics
directed at the homo- and/or heterodimer interface. Another utility based on these data
would be to engineer dimer-enhancing mutants, for example, EGFR mutants with the
equivalent ErbB2 D256/E259 substitutions. However, in addition to the fact that none of
the hypothesized enhancing mutants were predicted to behave, it is even more
challenging to achieve in practice since optimizing an interface by a two-amino acid
substitution is fundamentally much less likely to be detectable (even if theoretically
correct) than disrupting an interface. While favorable arm-armpit interaction is necessary,
there are additional contributions from other domains of the receptor that together, drive
the dimerization of full-length ErbB receptors in living cells. We, therefore, limited the
utility of this work within the scope of disrupting the interface for therapeutic
implications.
Methods
Computational Procedures
Homology modeling
Before homology modeling, flag tag residues DYKDDDDK at the end of the
ErbB2 structure (PDB 2A91, 2.5Å) was deleted because they were not part of the native
ErbB2 sequence. The resulting PDB file contained residues 1-509. Missing residues 103106 and all other missing atoms were initially filled in using PLOP v7.7147 and
subsequently minimized using Macromodel v9.1 with the rest of the atoms frozen.
Sequence alignment of the residues in 1IVO and 2A91 were constructed using the
ClustalW2 webserver148. Based on the sequence alignment, ErbB2 was homology
modeled onto the EGFR homodimer template (PDB 1IVO) using Modeller v9.5149 with

83

loop refinement on the EGFR and ErBb2 arm regions. 10 models were generated and the
model with the best DOPE score was selected as the starting structure for MD.
Molecular dynamic simulation
MD simulations were performed using Gromacs v3.3.3150 using OPLS2001
forcefield151. The EGFR-ErbB2 model was solvated in a dodecahedron periodic box of
pre-equilibrated TIP5P water molecules152. Ions were added to neutralize the system. The
protein complex is 14 Å away from the edge of the box in all directions. Following
minimization, the system was gradually heated up starting from 50K at intervals of 50K
for 30 ps each to reach the final temperature of 300K under NPT (Berendsen temperature
coupling every 0.1 ps and Parrinello-Rahman pressure coupling at 1 atm every 1 ps). The
initial velocity was randomly assigned from the Maxwell distribution at 50K. All stages
of the simulations were performed with the following setup: 2 fs time step; LINCS bond
length constraints; PME electrostatic treatment with grid spacing of 0.12; PME order of 6
and damping starting at 9 Å; van der Waal treatment was truncated at 9 Å. The
heterodimer simulation was for 9.9 ns and the homodimer simulation was for 15 ns. All
simulations were performed on the NSF Teragrid153 spanning several months.
MM/PBSA
Theory. The Molecular Mechanics/Poisson Boltzmann Solvent Accessible
(MM/PBSA) protocol131,

154

, shown to be fast and effective120,

155-157

in many cases,

calculates the relative binding free energies between biomolecular complexes by
decomposing it into the sum of solvation and gas-phase terms (AB denotes to complex, A
and B denotes to sub-components of the complex):
ΔbindG = ΔgasG + (ΔsolvationGAB – ΔsolvationGA– ΔsolvationGB) (equation 1)
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Solvation energy is further decomposed into polar and apolar components:
ΔsolvationG = ΔPBG + γΔSASAA (equation 2)
Polar or electrostatic contribution is calculated by the Poisson-Boltzmann method (PB)
using a continuum implicit-solvent model. The apolar component is estimated by
weighting the change in solvent-accessible surface area (SASA) by a heuristic surface
tension term, A.
The gas-phase term is calculated as:
ΔgasG = ΔgasU + TΔS (equation 3)
The gas-phase potential energy (U) is calculated based on semi-empirical force field
energy. Treatment of entropy is assumed to be relatively equivalent across mutants and
global structural is preserved.
The final binding energy is the average of the ensemble, and the relative binding
energy is the difference between the wildtype ensemble and the mutant ensemble. The
relative binding energy is used to predict the relative stability of the mutant complex with
respect to the wildtype complex.
Implementations. Representative snapshots of the MD trajectory were extracted
every 50 ps starting from 3500 ps for a total of 130 frames for heterodimer simulation,
and every 100 ps starting from 2000 ps for a total of 129 frames for homodimer
simulation. PDB files were converted to PQR files by PDB2PQR158

v1.3.0 using

OPLS2001 charge and PARSE radii159. Mutations were done by using PLOP147 v15.19
with intra-protein dielectric constant of 2 and solvent dielectric constant of 80. In all
cases, side chains within 15 Å of the mutated residue were repacked and minimized.
Solvent-accessible surface area was calculated by using the acc module of APBS160
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v1.1.0. Molecular mechanic energy components were calculated using Gromacs v3.3.3.
Because the size of the dimer system, regular PB calculation using APBS required
impractical amount of memory and CPU time using the desired grid spacing. Instead,
calculations were performed using the asynchronous mode of APBS by dividing the
system that resulted in 64 calculations per snapshot, 8320 calculations per mutant, and
~100,000 calculations in total. Each column listed in the tables was calculated as the
average of all values calculated from each frame with outliers removed.
The experimental binding energies for the control mutants were calculated based
on the KD42 and the monomer:dimer ratio46 using equations: ΔG=-RTln(KD) and ΔG=RTln([monomer]2/[dimer]). Normalization with respect to the control case in each
experiment was performed to compare the two experiments on the same scale.
Calculation using the backrub module of Rosetta
The same set of snapshots extracted from the MD trajectories were first relaxed
by Rosetta132, 161 v3.0 scoring functions with the backbone atoms fixed. Mutations were
constructed and optimized using the BACKRUB module. For each mutation, at least 3
residues were selected for backrub motions and only those residues were subjected for
backbone and side-chain repacking. All optimizations were performed on the complex
only; monomers were extracted from the optimized complex and not subjected to
optimization as this yielded the best results in our experience and as previously
suggested162. The final stability score of the complex was calculated by subtracting the
scores of the monomers from the complex
Experimental Procedures
Reagents
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Murine EGF was purchased from Biomedical Technologies, Inc. and was
dissolved in sterile water. Doxycycline was purchased from Clontech and was dissolved
in sterile water. D-Luciferin (Biosynth) was dissolved in PBS and coelenterazine (Sigma)
was dissolved in ethanol. The phosphotyrosine antibody (PY20) was from BD
Biosciences. The EGF receptor and ErbB2 antibodies were from Upstate.
DNA Constructs
The D256A/E259A, D256N/E259Q, D256R/E256K, D256T/E259Q-ErbB2
constructs were made using QuikChange site-directed mutagenesis (Stratagene) in the
ErbB2 pcDNA3.1(+) construct (kind gift from Dr. Graham Carpenter, Vanderbilt
University). The ErbB2 mutants were ligated into pcDNA5.FRT (Invitrogen) using the
NheI and XhoI sites. All mutantions were verified by sequencing.
Cell Lines
CHO-K1 Tet-On cells (Clontech) were stably transfected with pTK-Hyg
(Clontech) and K721A-EGFR (pBI-Tet MCSI) using Lipofectamine 2000 (Invitrogen) as
previously described92. CHO-K1 Tet-On cells were cotransfected with pTK-Hyg and ΔCEGFR-NLuc (pBI-Tet MCSI) using Lipofectamine 2000 as previously described81. A
double-stable cell line was established by transfecting ΔC-EGFR-CLuc (pcDNA4/mycHisB, Invitrogen) into ΔC-EGFR-NLuc cells using Lipofectamine 2000 and selecting in
400 µg/ml zeocin (Invitrogen). Double-stable lines were maintained in DMEM
containing 10% FetalPlex, 1000 µg/ml penicillin/streptomycin, 100 µg/ml G418, 50
µg/ml hygromycin, and 100 µg/ml Zeocin.
Wild-type ErbB2 (pcDNA3.1+), the ErbB2 mutants (pcDNA5.FRT), wild-type
EGFR (pcDNA5.FRT), or the empty pcDNA5.FRT vector were transiently transfected

87

into the K721A-EGFR or the ΔC-EGFR-NLuc/CLuc cell line 24 hr prior to assay using
Lipofectamine 2000. For the transfection into the ΔC-EGFR-NLuc/CLuc cell line, cells
were co-transfected with renilla luciferase (pRLuc-N1, Packard Bioscience) to assess the
transfection efficiency using bioluminescence imaging.
Kinase activation and Western Blotting
K721A-EGFR cells were grown to confluence in 35 mm dishes. Cells were
serum-starved in DMEM containing 1 mg/ml BSA for 2 hr. Culture medium was
removed and cells were washed twice in ice-cold PBS and then scraped into RIPA buffer
(150 mM NaCl, 10 mM Tris pH 7.2, 0.1% sodium dodecysulfate, 1% Triton X-100, 17
mM deoxycholate, and 2.7 mM EDTA) containing 20 mM p-nitrophenyl phosphate, 1
mM sodium orthovanadate, and protease inhibitors. Equal amounts of protein (BCA
assay, Pierce) were loaded onto a 9% SDS-polyacrylamide gel and then transferred to
PVDF (Millipore). Western blots were blocked for 1 hour in TBST/10% nonfat milk. The
blots were incubated in primary antibody for 1 hr, washed in TBST/0.1% BSA, incubated
in secondary antibody for 45 min and washed three times in TBST/0.1% BSA. Western
blots were detected using the ECL reagent from GE Healthcare.
Luciferase complementation imaging
Luciferase fragment complementation imaging was done as previously
described81. Briefly, cells were plated 48 hr prior to use at 5 x 103 cells per well in
DMEM containing 1 µg/ml doxycycline in a black-walled 96-well plate. On the day of
the assay, cells were serum-starved for 2 hr and then incubated for 20 min in 175 µl
DMEM without phenol red, containing 1 mg/ml BSA, 25 mM Hepes, and 0.6 mg/ml Dluciferin at 37ºC. To establish a baseline, cell radiance (photons/second/cm2/sr) was

88

measured using a cooled CCD camera and imaging system at 37ºC (IVIS 50; Caliper) (30
sec exposure; binning, 8; no filter; f-stop, 1; field of view 12 cm). EGF was added in a
volume of 25 µl in the same media (DMEM, 1 mg/ml BSA, 25 mM Hepes, 0.6 mg/ml DLuciferin). Radiance was measured sequentially as described above. To assess the
transient transfection efficiency, renilla luciferase expression was monitored. Media was
replaced on cells with DMEM (no phenol red) containing 1 mg/ml BSA, 25 mM Hepes,
and 400 nM coelenterazine. Radiance was immediately measured as described above
except the filter was set to <510.
Data Analysis
Data was collected in quadruplicate for each condition. A flat-field correction was
done to correct for differences in the baseline photon flux. Light production expressed as
photon flux (photons/sec) was determined from regions-of-interest defined over wells
using LIVINGIMAGE (Xenogen) and IGOR (Wavemetrics) software. Changes in photon
flux were calculated by subtracting values from untreated cells from those of EGF-treated
cells. Standard errors were determined using the formula for the calculation of the
unpooled standard error
Acknowledgement. The luciferase imaging assay was performed by Katy Yang.
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CHAPTER 5. Additional Hits and Discussions
Additional hits from structurally similar compounds
As discussed in Chapter 2, one of the advantages of screening the NCI-diversity
database was due to its large collection of structurally similar compounds corresponding
to each representative compound in the diversity set. We have followed up on one
identified lead compound, NSC56452, by searching the original NCI database for
additional compounds that share at least 90% Tanimoto similarity163 in structure and
composition. Because the luciferase fragment complementation assay was the faster and
superior screening method comparing to Western blotting for activation, our strategy was
to screen directly for dimerization inhibitors in the first pass at a single dose, followed by
dose-response characterization of subsequent candidates, and finally candidates could be
tested by Western blot to confirm inhibitory effect on receptor activation.
In addition to testing the NCI compounds, we also tested a compound set
originally synthesized as generic kinase inhibitors by Professor Stefan Laufer164, 165. The
motivation and the ensuing exciting direction originated from a structural search of our
lead compounds in the literature that lead to Professor Laufer’s publications. In these
articles, they described the synthesis and thorough characterization of the inhibition effect
of a set of compounds tested against a wide spectrum of kinases. This was particularly
interesting to us because while we are confident that NSC56452 blocks dimer formation
(as seen in kinase-deleted luciferase experiment, chapter 2), it would be intriguing to see
whether it has or may be modified to have additional activity against the kinase domain
of EGFR. Based on the structural resemblance between NSC56452 and the kinase
inhibitors synthesized by Laufer et al, the direction was then to explore the potentials of
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developing multi-targeting agents to increase potency. Given that substantial testing
against a wide range of kinase has already been done, the concept of multi-targeting
could be extended from targeting multiple domains of EGFR to include targeting multiple
kinase targets towards the development of “dirty drugs”166, 167.
Figure 5.1, Table 5.1 and Table 5.2 summarizes the data obtained so far from
testing these compounds. The original intent was to derive a pharmacophore model that
can discriminate against structurally close inactive compounds. Pharmacophore models
can then be utilized to provide a fast ligand-based filtering layer in our top-down
screening approach:
ligand-based virtual screening using pharmacophore models  receptor-based virtual
screening by the OpenScreening Project  testing of top candidates by the luciferase
fragment complementation imaging assay  biochemical characterization to assess
inhibitory activities.
However, preliminary development of these pharmacophore models has so far
yielded sub-optimal predicative power largely due to the potentially narrow range in IC50
values among compounds. The definition of “actives” and “inactives” in constructing
ligand-based models often requires the difference in potency to be of several orders of
magnitudes. Testing at a wider dose range is therefore warranted in order to derive more
sensitive models
Future direction
The lead inhibitors of EGFR homodimer serve as a proof-of-concept for targeting
the dimerization interface with small-molecule inhibitors. I envision two immediate
directions to build on this thesis: 1) continuous optimization of the lead compounds with
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the help of descriptive pharmacophore model, and 2) peptidomimetic design based on the
dimerization arm difference to target homo- and heterodimer interface. The benefit of
having the luciferase complementation assay readily available should provide a great
platform for immediate testing of potential candidates. The next milestone should be the
characterization of the compounds (ideally, second-generation compounds more potent
than the initial lead compounds) against purified extracellular domain of EGFR to test the
so-far-consistent hypothesis that they target the dimerization arm interface. Crystal
complex would be ideal, however, potentially difficult considering the balance between
the concentration of extracellular domain needed to form crystals and the concentration
of inhibitors necessary to prevent dimer formation
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Figure 5.1. Graphical summary of the screening results. Compound 47 is the control
with DMSO; compound 53 (*) is the tyrosine kinase inhibitor erlotinib. Compounds
showing effect below 25% was denoted as (+++) in Table 5.1, 50% denoted as (++),
75% denoted as (+). Experiment was done in triplicate of 3 wells at concentration of
25 µM compound.
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Table 5.1. Screening results of NCI compounds and selected Laufer compounds
Compound ID

Graph No.

Structure

34489

2

+++

DH193

3

5 μM

49818

4

+++

94

-/+ or IC50

Compound ID

Graph No.

Structure

47777

5

++

48720

6

++

43414

7

++

95

-/+ or IC50

Compound ID

Graph No.

Structure

49817

8

++

44580

9

++

44582

10

++

96

-/+ or IC50

Compound ID

Graph No.

Structure

56453

11

++

42381

12

++

42379

13

++

97

-/+ or IC50

Compound ID

Graph No.

Structure

59485

14

144 nM

44583

15

++

49819

16

++

48724

17

++

98

-/+ or IC50

Compound ID

Graph No.

Structure

DH29

18

++

58908

19

++

45156

20

++

99

-/+ or IC50

Compound ID

Graph No.

Structure

36828

21

++

43415

22

++

48715

23

++

100

-/+ or IC50

Compound ID

Graph No.

Structure

56452

24

0.6 μM

47779

25

++

45155

26

+

11421

27

+

101

-/+ or IC50

Compound ID

Graph No.

Structure

DH14

28

3 μM

48718

29

+

49820

30

+

102

-/+ or IC50

Compound ID

Graph No.

Structure

48722

31

+

DH199

32

4 μM

42380

33

76 μM

47782

34

+

103

-/+ or IC50

Compound ID

Graph No.

Structure

DH202

35

+

DH250

36

+

48714

37

+

DH262

38

+/-

104

-/+ or IC50

Compound ID

Graph No.

Structure

47786

39

+/-

DH73B

40

+/-

DH172

41

+/-

AG1478

42

+/-

105

-/+ or IC50

Compound ID

Graph No.

Structure

38303

43

+/-

DH156

44

+/-

DH36

45

-

42382

46

-

106

-/+ or IC50

Compound ID

Graph No.

Structure

DH50

48

-

42384

49

-

43412

50

-

DH251

51

-

107

-/+ or IC50

Compound ID

Graph No.

Structure

42383

52

-

Tarceva

53

-

43411

54

-

DH2

55

-

108

-/+ or IC50

Compound ID

Graph No.

Structure

DH12

56

-

49821

57

-

29421

58

18 mM

47783

59

-

109

-/+ or IC50

Compound ID

Graph No.

Structure

46383

60

-

DH42

61

-

46384

62

-

110

-/+ or IC50

Compound ID

Graph No.

Structure

15747

63

-

DH168

64

-

DH144

65

-

DH58A

66

-

111

-/+ or IC50

Compound ID

Graph No.

48713

67

Structure

-/+ or IC50

-

Compound 1 is positive control, Cetuximab; Compound 47 is control with DMSO;
Compound 53 is negative control, Tarceva.
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Table 5.2. Screening results of all Laufer compounds at dose of 20 µM.
Publication ID

Internal
ID

Phenyl-(9H-purin6-yl)-amin

2 (1)

DH 1

-

(4-Fluor-phenyl)(9H-purin-6-yl)amin

3 (2)

DH 2

-

(9-Methyl-9Hpurin-6-yl)-phenylamin

4 (5)

DH 14

++

(4-Fluor-phenyl)(9-methyl-9Hpurin-6-yl)-amin

5 (6)

DH 29

++

6-Phenoxy-9Hpurin

9 (3)

DH 3

-

6-(4-Fluorphenoxy)-9H-purin

10 (4)

DH 4

-

IUPAC

113

Structures

Activity

6-Phenylsulfanyl9H-purin

11 (7)

DH 33

-

6-(4-Fluorphenylsulfanyl)9H-purin

12 (8)

DH 34

-

9-Methyl-6phenylsulfanyl-9Hpurin

13 (11)

DH 36

+/-

6-(4-Fluorphenylsulfanyl)-9methyl-9H-purin

14 (12)

DH 35

-

4-Phenylsulfanyl7H-pyrrolo[2,3d]pyrimidin

20 (9)

DH 143

-

4-(4-Fluorphenylsulfanyl)7H-pyrrolo[2,3d]pyrimidin

21 (10)

DH 144

-

114

6-Benzyl-9H-purin

25 (29)

DH 181

-

6-(4-Fluor-benzyl)9H-purin

26 (30)

DH 196

-

6-Styryl-9H-purin

27 (31)

DH 193

++

6-[2-(4-Fluorphenyl)-vinyl]-9Hpurin

28

DH 240

-

9-Methyl-6-styryl9H-purin

29 (32)

DH 128

-

6-Benzylsulfanyl9H-purin

31 (13)
nsc29421

DH 17

-

115

6-(4-Fluorbenzylsulfanyl)9H-purin

32 (14)

DH 18

-

6-Benzylsulfanyl9-methyl-9H-purin

33 (15)
nsc38303

DH 42

-

6-(4-Fluorbenzylsulfanyl)-9methyl-9H-purin

34 (16)

DH 41

-

9-Methyl-6-phenyl9H-purin

41 (39)

DH 70

-

6-(4-Fluor-phenyl)9-methyl-9H-purin

42 (40)

DH 69

-

7-Phenyl-7H-purin

45 (19)

DH 12

-

116

7-(4-Fluor-phenyl)7H-purin

46 (20)

DH 11

-

7-Benzyl-7H-purin

49 (17)

DH 53

-

DH 55

-

7-(4-Fluor-benzyl)7H-purin

(18)

7 Benzyl 6 chlor
7H purin

51 (22)

DH 58B

-

6 Chlor (4 fluor
benzyl) 7H purin

52 (24)

DH 59B

-

7-(4-Fluor-benzyl)7H-purin-6-ylamin

53 (27)

DH 73A

-

117

7 (4 Fluor benzyl)
6 methoxy
7H purin

54 (28)

DH 73B

+/-

9-Benzyl-6-chlor9H-purinund

55 (21)

DH 58A

-

6-Chlor-9-(4-fluorbenzyl)-9H-purin

56 (23)

DH 59A

-

9-Benzyl-9Hpurin-6-ylamin

57 (25)

DH 74

-

9-(4-Fluor-benzyl)9H-purin-6-ylamin

58 (26)

DH 72

-

6-(4-Fluor-phenyl)9-methyl-8-phenyl9H-purin

59 (41)

DH 71

-

118

9-Methyl-8-phenyl6-phenylsulfanyl9H-purin

66 (44)

DH 50

-

6-(4-Fluorphenylsulfanyl)-9methyl-8-phenyl9H-purin

67 (45)

DH 57

-

9-Methyl-8-(4methylsulfanylphenyl)-6phenylsulfanyl-9Hpurin

68 (49)

DH 154

-

6-(4-Fluorphenylsulfanyl)-9methyl-8-(4methylsulfanylphenyl)-9H-purin

69 (50)

DH 156

-

8-(4Methansulfinylphenyl)-9-methyl6-phenylsulfanyl9H-purin

70 (51)

DH 167

-

6-(4-Fluorphenylsulfanyl)-8(4-methan-sulfinylphenyl)-9-methyl9H-purin

71 (52)

DH 168

-

119

8-(4Methansulfonylphenyl)-9-methyl6-phenylsulfanyl9H-purin

72 (53)

DH 171

-

6-(4-Fluorphenylsulfanyl)-8(4-methansulfonylphenyl)-9-methyl9H-purin

73 (54)

DH 172

-

8-(4Methylsulfanylphenyl)-6phenylsulfanyl-9Hpurin

76

DH 180

-

8-Brom-9-methyl6-phenylsulfanyl9H-purin

78 (55)

DH 216

-

4-(9-Methyl-6phenylsulfanyl-9Hpurin-8-yl)-but-3yn-1-ol

79 (56)

DH 217

-

9-Benzyl-6phenylsulfanyl-9Hpurin

80 (57)

DH 199

++

120

9-Benzyl-6-(4fluorphenylsulfanyl)9H-purin

81 (58)

DH 202

++

9-(4-Fluor-benzyl)6-phenylsulfanyl9H-purin

82 (59)

DH 203

+/-

9-(4-Fluor-benzyl)6-(4-fluorphenylsulfanyl)9H-purin

83 (60)

DH 204

-

6-(2-Chlorphenyl)-9-(2,6difluor-phenyl)7,9-dihydro-purin8-on

104 (21, ref2) DH 227

-

6-(2-Chlorphenyl)-9-(2,6dimethyl-phenyl)7,9-dihydro-purin8-on

105 (22, ref2) DH 262

+/-

121

6-(2-Chlorphenyl)-9-(2,4difluor-phenyl)7,9-dihydro-purin8-on

106 (23, ref2) DH 238

-

9-(2,6-Difluorphenyl)-6-phenyl7,9-dihydro-purin8-on

107 (24, ref2) DH 233

-

9-(2,6-Dimethylphenyl)-6-o-tolyl7,9-dihydro-purin8-on

108 (25, ref2) DH 250

-

9-(2,6-Dimethylphenyl)-6-o-tolyl7,9-dihydro-purin8-thion

9-(2,6-Difluorphenyl)-6-o-tolyl7,9-dihydro-purin8-on

109

DH 251

-

110 (26, ref2) DH 237

-

122

9-(2,6-Difluorophenyl)-6-o-tolyl7,9-dihydro-purin8-on

111 (27, ref2) DH 244

9-(2,4-Dimethoxyphenyl)-6-o-tolyl112 (28, ref2) DH 249
7,9-dihydro-purin8-on

9-(2,6-Difluorphenyl)-6-(2-fluor113 (29, ref2) DH 275
phenyl)-7,9dihydro-purin-8-on

-

-

-

1-(2,6-Difluorphenyl)-5-o-tolyl3,4-dihydro-1Hpyrimido[4,5
d]pyrimidin-2-on

121

DH 321

-

5-(2-Chlorphenyl)-1-(2,6difluor-phenyl)3,4-dihydro-1H
pyrimido[4,5
d]pyrimidin-2-on

122

DH 332

-

123

Publication ID numbers are given by Professor Laufer, ID in brackets are the actual IDs
assigned in the final print of their publication164. Some compounds were published in a
separate publication165, denoted as ref2 in the table. Compounds were initially tested as a
pair, and pairs that tested positive were then subjected for individual testing.
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